TABLE OF CONTENTS
Volume 65, Issue 2 (February 1999)
Notes of the American Society for Clinical Pharmacology and Therapeutics |
Abstracts
American Society for Clinical Pharmacology and Therapeutics
Onset of action defined by patients.
B.P. Schachtel MD, I. Loose MD, PhD, A.T. Brown RN and K.M. Sanner RN
Clin Pharmacol Ther 65: 117; doi:10.1016/S0009-9236(99)80001-0
Demonstration of dose-response of flurbiprofen lozenge for sore throat.
B.P. Schachtel MD, H.D. Homan PhD, I.A. Gibb PhD and J. Christian BSc
Clin Pharmacol Ther 65: 117; doi:10.1016/S0009-9236(99)80002-2
Baseline pain and response to medications in post surgery dental pain model.
M. Averbuch MD, M. Katzper PhD and C. Fang MD
Clin Pharmacol Ther 65: 118; doi:10.1016/S0009-9236(99)80003-4
MK-0966 50 MG versus ibuprofen 400 MG in post surgical dental pain.
Jean Brown RN, Briggs W. Morrison MD, Steven Christensen DDS, Vickie Dunkley RN, Michael Sandler, Mindi Turpin RN, Becca Harmsen RN, Weiying Yuan PhD, Lee Lesneski RN and Beth Seidenberg MD
Clin Pharmacol Ther 65: 118; doi:10.1016/S0009-9236(99)80004-6
The COX-2 specific inhibitor, MK-0966, is effective in the treatment of primary dysmenorrhea.
Jean Brown RN, Briggs W. Morrison MD, Mark Bitner MD, Carl Woolsey MD, Michael Sandler, Vickie Dunkley RN, Paul Kotey PhD and Beth Seldenberg MD
Clin Pharmacol Ther 65: 118; doi:10.1016/S0009-9236(99)80005-8
Dose ranging trial of the effect of MK-966 in primary dysmenorrhea.
Stephen Daniels DO, Briggs W. Morrison MD, Norma Cantu RN, Michael Sandler, Lisa McCrary, Paul Kotey PhD and Beth Seidenberg MD
Clin Pharmacol Ther 65: 118; doi:10.1016/S0009-9236(99)80006-X
MK-966 versus naproxen sodium, 550 MG in post-surgical dental pain.
James Fricke DDS, Briggs W. Morrison MD, Skip Fite RN, Michael Sandler, Weiying Yuan PhD, Cynthia Howard and Beth Seidenberg MD
Clin Pharmacol Ther 65: 119; doi:10.1016/S0009-9236(99)80007-1
Lanepitant, an NK-1 antagonist, in painful diabetic neuropathy.
D.J. Goldstein MD, PhD and O. Wang PhD
Clin Pharmacol Ther 65: 119; doi:10.1016/S0009-9236(99)80008-3
Quantifying analgesic onset in the oral surgery model.
S.M. Gordon DDS, MPH, J.S. Brahim DDS, MS, A.A. Kent and R.A. Dionne DDS, PhD
Clin Pharmacol Ther 65: 119; doi:10.1016/S0009-9236(99)80009-5
Dexibuprofen lysine versus ibuprofen for headache.
S.H. Korn MD, E.B. Horne PharmD, K. McCarroll PhD, M. Villani BSN and S.J. Larouche MD
Clin Pharmacol Ther 65: 119; doi:10.1016/S0009-9236(99)80010-1
Controlled trial of cyclobenzaprine for acute musculoskeletal spasm.
S.J. Larouche MD, G. Block MD, PhD, S. Raskin MS, S. Ahrens BS and S. Korn MD
Clin Pharmacol Ther 65: 120; doi:10.1016/S0009-9236(99)80011-3
Oxaprozin potassium compared with oxycodone/acetaminophen for management of post-operative pain.
D.R. Mehlisch MD, DDS, S.E. Daniels DO, D.R. Baum, T. Bocanegra MD and S. Rush RN
Clin Pharmacol Ther 65: 120; doi:10.1016/S0009-9236(99)80012-5
An evaluation of buffered ketoprofen in postoperative dental pain.
R.A. Seymour PhD and J.E. Hawkesford FDS
Clin Pharmacol Ther 65: 120; doi:10.1016/S0009-9236(99)80013-7
Efficacy and safety evaluation of hydrocodone bitartrate with ibuprofen vs. oxycodone HCl with acetaminophen in acute postoperative pain.
G. Wideman MD, M. Keffer RN, R. Doyle BA, E. Morris RPh, P. Patel BS and J. Jiang PhD
Clin Pharmacol Ther 65: 120; doi:10.1016/S0009-9236(99)80014-9
Altered absorption and metabolism of ibuprofen caused by dental surgery.
F. Jamali, H. Kola, M. Guiguis, M. Grace and G.W. Reborn
Clin Pharmacol Ther 65: 121; doi:10.1016/S0009-9236(99)80015-0
The substrate-independence assumption of the relative activity factor (RAF) approach.
Karthik Venkatakrishnan, Lisa L. Von Moltke and David J. Greenblatt
Clin Pharmacol Ther 65: 121; doi:10.1016/S0009-9236(99)80016-2
The mixed analgesic effects of tramadol enantiomers.
J. Desmeules MD, C. Violand MD, V. Piguet MD, M. Kondo Oestreicher, N. Cheseaux MD and P. Dayer MD
Clin Pharmacol Ther 65: 121; doi:10.1016/S0009-9236(99)80017-4
Population pharmacokinetics of o-demethyl metabolite (M1) of tramadol in patients after dental extraction.
Tsang-Bin Tzeng PhD, Yuzhu Xue, Michael Borenstein PhD and Samuel Liao PhD
Clin Pharmacol Ther 65: 121; doi:10.1016/S0009-9236(99)80018-6
Lack of pharmacokinetic interaction between morphine and dextromethorphan in healthy volunteers.
F.S. Caruso PhD, D.A. Johnson PhD and P.K. Noonan PhD
Clin Pharmacol Ther 65: 122; doi:10.1016/S0009-9236(99)80019-8
Population pharmacokinetics of tramadol and acetaminophen given orally as a single dose combination tablet in healthy volunteers.
S. Liao PhD, X. Li MS and K. Larson MS
Clin Pharmacol Ther 65: 122; doi:10.1016/S0009-9236(99)80020-4
Evaluating the effects of topically applied products on superficial skin wounds.
A.M. Kligman MD, PhD, M. Stoudemayer BS, L DeShields MS and R. Maas-Irslinger MD
Clin Pharmacol Ther 65: 122; doi:10.1016/S0009-9236(99)80021-6
A comparison of the efficacy of 
-ketobutyric acid (KBA), nordihidro-guaiaretic acid (NDGA), salicylic acid (SA), and placebo (P) in the accelerated removal of corns.
K.M. Williams, R.O. Day, L.K. Roberts and J.A. Harbin
Clin Pharmacol Ther 65: 122; doi:10.1016/S0009-9236(99)80022-8
Study of pharmacodynamics of skin using in-vivo confocal scanning laser microscopy.
I. Sadiq MS, D. Kligman MD, PhD, A. Pagnoni MD, K. Costa PhD, O.H. Mills Jr. PhD, FCP, T. Stoudemayer and A.M. Kligman MD, PhD
Clin Pharmacol Ther 65: 123; doi:10.1016/S0009-9236(99)80023-X
Post-adolescent female acne: Developing treatment guidelines based on epidemiological data.
O.H. Mills Jr. PhD, FCP, R.S. Berger MD and A.M. Kligman MD, PhD
Clin Pharmacol Ther 65: 123; doi:10.1016/S0009-9236(99)80024-1
Method to assess bioequivalence (BE) of topically delivered drug by intradermal microdialysis (IDM).
G. Stagni PhD and A.M.M. Shepherd MD, PhD
Clin Pharmacol Ther 65: 123; doi:10.1016/S0009-9236(99)80025-3
Effect of lactic acidosis on lidocaine (L) red cell distribution in pigs.
H. Zhao PhD and M.S.S. Chow PharmD
Clin Pharmacol Ther 65: 123; doi:10.1016/S0009-9236(99)80026-5
A steroid "Deport" in the stratum corneum and the adequacy of once-daily topical application.
K.A. Costa PhD, T. Stoudemayer and A.M. Kligman MD, PhD
Clin Pharmacol Ther 65: 124; doi:10.1016/S0009-9236(99)80027-7
Characterization of uridine transport properties by a rat intestinal epithelial cell line (IEC-6).
L. Yeung, S. Leung BSc and R. Bendayan PharmD
Clin Pharmacol Ther 65: 124; doi:10.1016/S0009-9236(99)80028-9
Mibefradil is a potent inhibitor of both CYP3A and P-glycoprotein (P-GP).
C. Wandel MD, R.B. Kim MD, F.P. Guengerich PhD and A.J.J. Wood MD
Clin Pharmacol Ther 65: 124; doi:10.1016/S0009-9236(99)80029-0
Transport properties of thymidine by a rat microglia cell line.
M. Hong BSc, L. Schlichter PhD, P. Pennefather PhD and R. Bendayan PharmD
Clin Pharmacol Ther 65: 124; doi:10.1016/S0009-9236(99)80030-7
Uptake properties of zidovudine (ZDV) by an HIV-I target brain parenchyma cell line.
M. Hong BSc, L. Schlichter PhD, P. Pennefather PhD and R. Bendayan PharmD
Clin Pharmacol Ther 65: 125; doi:10.1016/S0009-9236(99)80031-9
Pharmacologic modulation of P-glycoprotein (PGP) expression: An alternative approach to improve the penetration of drugs.
B.P. Kearney PharmD and J.G. Gambertoglio PharmD
Clin Pharmacol Ther 65: 125; doi:10.1016/S0009-9236(99)80032-0
Molecular cloning, genomic organization, and tissue distribution of the human MRP3 transporter and its splice variants.
M.F. Fromm MD, B. Leake BSc, D.M. Roden MD, G.R. Wilkinson PhD and R.B. Kim MD
Clin Pharmacol Ther 65: 125; doi:10.1016/S0009-9236(99)80033-2
Is P-glycoprotein (P-gp) involved in the renal tubular transport of nucleoside analog drugs (NADs)?
S. Leung BSc and R. Bendayan PharmD
Clin Pharmacol Ther 65: 125; doi:10.1016/S0009-9236(99)80034-4
Phase 1, randomized, parallel, placebo-controlled, safety, tolerance and pharmacokinetic study of multiple dose of IY-81149 in fasting male volunteers.
R. Goldwater MD, F. Boileau MSc, S.M. Lee PhD, G.J. Chung MSc, D.Y. Kim PhD and K.D. Cho BSc
Clin Pharmacol Ther 65: 126; doi:10.1016/S0009-9236(99)80034-4
A phase 1, randomized, parallel, placebo-controlled, safety, tolerance and pharmacokinetic study of single ascending doses of IY-81149 in fasting male volunteers.
R. Goldwater MD, F. Boileau MSc, S.M. Lee PhD, G.J. Chunt MSc, D.Y. Kim PhD and K.D. Cho BSc
Clin Pharmacol Ther 65: 126; doi:10.1016/S0009-9236(99)80035-6
Substrate specificity of the rat organic anion transporting polypeptides oapt1, oatp2 and the human OATP.
K.E. Fattinger MD, J.E. van Montfoort, B. Hagenbuch PhD, D.K.F. Meijer PhD, B. Stieger PhD and P.J. Meier MD
Clin Pharmacol Ther 65: 126; doi:10.1016/S0009-9236(99)80037-X
Identification and characterization of human cytchrome P450 (CYP) isoforms interacting with cisapride.
Zeruesenay Desta, David Thacker, Nadia Soukhova, Jae-Gook Shin and David A. Flockhart
Clin Pharmacol Ther 65: 126; doi:10.1016/S0009-9236(99)80038-1
Cisapride (CIS) biotransformation: Not all CYP3As are created equal.
R.R. Gotschall M.S., K. Marcucci B.S., J.S. Leeder PharmD, PhD and G.L. Kearns PharmD
Clin Pharmacol Ther 65: 127; doi:10.1016/S0009-9236(99)80039-3
Shedded enterocytes as an ex vivo probe for gut wall metabolism.
B. Greiner MD, O.V. Richter, T. Omari PhD, J. Dent MD, A. Somogyi PhD and M. Eichelbaum MD
Clin Pharmacol Ther 65: 127; doi:10.1016/S0009-9236(99)80040-X
Metabolism and transport of drugs in the human intestine studied with a perfusion catheter.
O. Von Richter, B. Greiner MD, T. Omari PhD, J. Dent MD, A. Somogyi PhD and M. Eichelbaum MD
Clin Pharmacol Ther 65: 127; doi:10.1016/S0009-9236(99)80041-1
The pharmacokinetics of omeprazole in relation to the genotypes of the S-mephenytoin hydroxylase.
S. Chai MSc, J.-T. Kwon MD, D.-G. Yang MD, H.-K. Kim MD and D.-R. Sohn MD
Clin Pharmacol Ther 65: 127; doi:10.1016/S0009-9236(99)80042-3
Drug Interaction between Omeprazole and Clarithromycin with Relation to CYP2C19 Status
K. Ohashi MD, T. Furuta MD, K. Kobayashi PhD, K. Kosuge PhD and K. Kaneko MD
Clin Pharmacol Ther 65: 128; doi:10.1016/S0009-9236(99)80043-5
Single- and Multiple-Dose Pharmacokinetics of Sdz Htf 919 In Healthy Subjects
S. Appel-Dingemanse PhD, M. Guerret PhD, Y. Hirschberg MSc and J. McLeod MD
Clin Pharmacol Ther 65: 128; doi:10.1016/S0009-9236(99)80044-7
Pharmacokinetics of Dexmedetomidine (DEX) in Patients with Hepatic Failure (HF)
F.E. Cunningham PharmD, V.L. Baughman MD, L. Tonkovich PharmD, N. Lam PharmD and T. Layden MD
Clin Pharmacol Ther 65: 128; doi:10.1016/S0009-9236(99)80045-9
Hepatitis B Immune Globulin (HBIG) Disposition After Liver Transplant (LT) in Chronic Hepatitis B (HBV)
M. Haug PharmD, M. Ishitani MD, S. Wimberley PharmD, W. Carey MD, D. Barnes MD, Z. Younossi MD, J. Mayes MD, M. Henderson MD and D. Vogt MD
Clin Pharmacol Ther 65: 128; doi:10.1016/S0009-9236(99)80046-0
Hepatic Impairment (HI) Studies Submitted in New Drug Applications (NDAs)
M. Mehta PhD, T. Parmelee PharmD, J.D. Balian MD and L. Lesko PhD
Clin Pharmacol Ther 65: 129; doi:10.1016/S0009-9236(99)80047-2
Lanepitant, An NK-1 Antagonist, in Migraine Prophylaxis
D.J. Goldstein MD, PhD, W.W. Offen PhD and E.G. Klein PharmD
Clin Pharmacol Ther 65: 129; doi:10.1016/S0009-9236(99)80048-4
Pharmacokinetics and Safety of LY334370, A Novel Oral 5-HT1F Selective Agonist, in Patients During Migraine
L.-A. Granier MD, J.-M. De Suray MS and A. Pereira PhD
Clin Pharmacol Ther 65: 129; doi:10.1016/S0009-9236(99)80049-6
Oxaprozin Potassium, Sumatriptan, and Placebo in Patients with Moderate or Severe Acute Migraine Headache
M.S. Weaver PhD, D.R. Mehlisch MD, DDS, T.S. Bocanegra MD, S.M. Hurley BS, S.M. Rush RN and K. Knopf MD
Clin Pharmacol Ther 65: 129; doi:10.1016/S0009-9236(99)80050-2
Safety, Absolute Bioavailability, and Dose Proportionality of BMS-181885 (I), A Novel 5HT1, Agonist, Following Intranasal (IN) Dosing in Humans
N. Srinivas, W. Shyu, S. Chang, I. Ferreira and D. Greene
Clin Pharmacol Ther 65: 130; doi:10.1016/S0009-9236(99)80051-4
Comparison of Ganaxolone Plasma Levels in Healthy Volunteers and Migraine Patients During A Migraine Attack
E.P. Monaghan PhD, K. Ramu PhD, K.D. Britch, G.N. Lam PhD, F.B. Weihmuller PhD, J. Goldstein MD and J.L. Data MD, PhD
Clin Pharmacol Ther 65: 130; doi:10.1016/S0009-9236(99)80052-6
Effect of Controlled-Onset Extended Release Verapamil (CODR-V) On Early Morning Rise In Blood Pressure and Forearm Vascular Resistance (FVR)
B.N. Nguyen PharmD, M. Noujedehi PharmD, R.B. Parker PharmD, J.M. Sullivan MD and J.A. Johnson PharmD
Clin Pharmacol Ther 65: 130; doi:10.1016/S0009-9236(99)80053-8
Pharmacological and Non-pharmacological Risk Factors For Hypertensive Crisis
J.E. Tisdale PharmD, M.B. Huang PharmD and S. Borzak MD
Clin Pharmacol Ther 65: 130; doi:10.1016/S0009-9236(99)80054-X
Effects Of Chronotherapeutic Delivery of Verapamil In Obese Vs Non-obese Patients With Hypertension
W.B. White MD, M.F. Johnson PhD and T.D. Fakouhi PhD
Clin Pharmacol Ther 65: 131; doi:10.1016/S0009-9236(99)80055-1
Omapatrilat Increases Key Vascular/Renal Markers Regardless Of Renal Function
J.L. Hammett MS, D.A. Sica MD, G. Scicli PhD, O.A. Carretero MD, F.A. Beierle PhD, C.L. Delaney MS, O. Vesterqvist PhD, J.A. Manning Jr. PhD, I.M. Ferreira PhD and W. Liao PhD, MD
Clin Pharmacol Ther 65: 131; doi:10.1016/S0009-9236(99)80056-3
Omapatrilat Does Not Affect The Steady-State Of Warfarin
B. Mangold MD, PhD, W. Gielsdorf PhD, J. Norton MS and W. Liao MD, PhD
Clin Pharmacol Ther 65: 131; doi:10.1016/S0009-9236(99)80057-5
Inhibition of Hepatic and Intestinal CYP3A4 by Mibefradil Measured by the Erythromycin Breath Test (EBT) and Oral Midazolam Pharmacokinetics (PK)
M.L. Veronese MD, L.P. Gillen MS, E.P. Dorval RN, W.W. Hauck PhD, S.A. Waldman MD, PhD and H.E. Greenberg MD
Clin Pharmacol Ther 65: 131; doi:10.1016/S0009-9236(99)80058-7
Steady State (SS) Pharmacokinetics (PK) of Irbesartan Alone and In Combination with Fluconazole (F)
S.J. Kovasc PharmD, J.H. Wilton PhD and R.A. Blum PharmD
Clin Pharmacol Ther 65: 132; doi:10.1016/S0009-9236(99)80059-9
Effect of Grapefruit Juice on the Pharmacokinetics of Losartan in Healthy Volunteers
R. Zaidenstein MD, B. Avni MD, V. Dishi MD, M. Gipps PhD, S. Soback DVM, PhD, M. Koren MD, R. Simantov MD and A. Golik MD
Clin Pharmacol Ther 65: 132; doi:10.1016/S0009-9236(99)80060-5
Pharmacodynamic Effects of Multiple Doses of Omapatrilat in Healthy Subjects
O. Vesterqvist PhD, W. Liao PhD, J.A. Manning PhD, H.D. Uderman MD, C.L. Delaney MS and B.N. Swanson PhD
Clin Pharmacol Ther 65: 132; doi:10.1016/S0009-9236(99)80061-7
Concentration-Effect (PK/PD) Relationships of Two Rilmenidine Infusions in Hypertension
N. Frey PharmD, M. Dubar PharmD, J.M.A. van Gerven MD, PhD, R.C. Schoemaker MSc, A.F. Cohen MD, PhD and R. Jochemsen PhD
Clin Pharmacol Ther 65: 132; doi:10.1016/S0009-9236(99)80062-9
Concentration-Effect-Relationships of Two Infusion Rates of Rilmenidine, for Blood Pressure and Sedation in Healthy Subjects
J.M.A. van Gerven MD, PhD, M. Dubar PharmD, N. Frey PharmD, R.C. Schoemaker MSc, R. Jochemsen PhD and A.F. Cohen MD, PhD
Clin Pharmacol Ther 65: 133; doi:10.1016/S0009-9236(99)80063-0
Beta-2 Adrenergic Receptor (BAR2) Poly-morphism is Not Associated with Essential Hypertension (HT) in African-Americans (AA) or Caucasian-Americans (CA)
H.G. Xie MD, PhD, R.B. Kim MD, C.M. Stein MD, J.V. Gainer MD, N.J. Brown MD, B. Leake MS and A.J.J. Wood MD
Clin Pharmacol Ther 65: 133; doi:10.1016/S0009-9236(99)80064-2
Interethnic Differences in Beta-2 Adrenoceptor (BAR2) Polymorphisms in African-American (AA), Caucasian (CA), and Chinese (CHN) Populations
H.G. Xie MD, PhD, R.B. Kim MD, C.M. Stein MD, J.V. Gainer MD, N.J. Brown MD, B. Leake MS, Z.S. Xiao MD, N. He MS, H.H. Zhou MD and A.J.J. Wood MD
Clin Pharmacol Ther 65: 133; doi:10.1016/S0009-9236(99)80065-4
Steady-State PK of Omapatrilat in Healthy Subjects
C.L. Delaney MS, M. Jemal PhD, F.A. Beierle PhD, I.M. Ferreira PhD, K.D. Davis MS, A. Meier BS, N.F. Ford MD, PhD, H.D. Uderman MD and W. Liao PhD, MD
Clin Pharmacol Ther 65: 133; doi:10.1016/S0009-9236(99)80066-6
The Effects of Renal Function on PK of Omapatrilat
B.K. Malhotra PhD, D.A. Sica MD, S. Khan PhD, C.L. Delaney MS, I.M. Ferreira PhD, J.L. Hammett MS, M. Jemal PhD and W. Liao PhD, MD
Clin Pharmacol Ther 65: 134; doi:10.1016/S0009-9236(99)80067-8
Gender Affects Bioavailability and Clearance of Verapamil
M.E. Krecic-Shepard PhD, C. Barnas MS, J. Slimko RN and J.B. Schwartz MD
Clin Pharmacol Ther 65: 134; doi:10.1016/S0009-9236(99)80068-X
Impact of Microscopy Error on Protective Efficacy Estimates in Malaria Prevention Trials
C. Ohrt MD, MPH and D. Tang PhD
Clin Pharmacol Ther 65: 134; doi:10.1016/S0009-9236(99)80069-1
Evaluation of Safety, PK, and PD of A New Quinolone Antibiotic, CFC-222, in Healthy Volunteers
K.S. Yu MD, K.S. Bae MD, I.J. Jang MD, Y.C. Lim MD, Y.R. Yoon MD and S.G. Shin MD
Clin Pharmacol Ther 65: 134; doi:10.1016/S0009-9236(99)80070-8
Inhibition of in Vitro HIV Transfer by a Topical Preparation of Benzalkonium Chloride and Octoxynol
J.A. Wijsman MSc and M.J. Rieder MD, PhD
Clin Pharmacol Ther 65: 135; doi:10.1016/S0009-9236(99)80071-X
Inhibition of Cytochrome P4502D6 (CYP2D6) by Terbinafine (TER) in Vitro
S.M. Abdel-Rahman PharmD, K. Marcucci BS, T. Boge PhD, R.R. Gotschall MS, G.L. Kearns PharmD and J.S. Leeder PharmD, PhD
Clin Pharmacol Ther 65: 135; doi:10.1016/S0009-9236(99)80072-1
Inhibition of Cytochrome P4502D6 (CYP2D6) by Terbinafine (TER) in Vivo
S.M. Abdel-Rahman PharmD, R.R. Gotschall MS, R.E. Kauffman MD, J.S. Leeder PharmD, PhD and G.L. Kearns PharmD
Clin Pharmacol Ther 65: 135; doi:10.1016/S0009-9236(99)80073-3
Lack of a Pharmacokinetic Interaction between Indinavir and Methadone
L. Cantilena MD, PhD, J. McCrea PharmD, D. Blazes MD, G. Winchell PhD, A. Carides PhD, C. Royce MSRN and P. Deutsch MD, PhD
Clin Pharmacol Ther 65: 135; doi:10.1016/S0009-9236(99)80074-5
Metabolism of An Anabolic Androgenic Steroid Oxymetholone by Human Cytochrome P450s
D.L. Thacker BSc, I. Wainer PhD, C. Lerch PharmD, K. Fried BSc and D.A. Flockhart MD, PhD
Clin Pharmacol Ther 65: 136; doi:10.1016/S0009-9236(99)80075-7
The Interaction between CYP3A Substrates in The Elderly
J.C. Gorski PhD, Z. Lin BS, M.A. Bruce MD, R. Craven RN, B.D. Haehner-Daniels MD and S.D. Hall PhD
Clin Pharmacol Ther 65: 136; doi:10.1016/S0009-9236(99)80076-9
Lack of Effect of HIV Protease Inhibitions on Sulfamethoxazole Hydroxylamine Production
A.M. Taburet PhD, K. Lecointre PharmD, V. Furlan PhD, C. Goujard MD and J.F. Delfraissy MD
Clin Pharmacol Ther 65: 136; doi:10.1016/S0009-9236(99)80077-0
The Effect of Clarithromycin on Human Cytochrome P450 (CYP) Enzymes
M.A. Bruce MD, J.C. Gorski PhD, Y. Liu MD, S.D. Hall PhD and B.D. Haehner-Daniels MD
Clin Pharmacol Ther 65: 136; doi:10.1016/S0009-9236(99)80078-2
Nevirapine Induces Both CYP3A4 and CYP2B6 Metabolic Pathways
M. Lamson PhD, T. MacGregor PhD, P. Riska, D. Erickson, P. Maxfield, L. Rowland, M. Gigliotti, P. Robinson MD, S. Azzam PhD and J. Keirns PhD
Clin Pharmacol Ther 65: 137; doi:10.1016/S0009-9236(99)80079-4
Inhibition of Enterotoxin-Stimulated Secretion in Caco-2 Cells by 2-Chloroadenosine
S. Schulz PhD, W. Zhang MD, I. Mannan MS, S. Parkinson PhD, A. Alekseev PhD, A. Terzic MD and S.A. Waldman MD, PhD
Clin Pharmacol Ther 65: 137; doi:10.1016/S0009-9236(99)80080-0
Absence of Apoptosis in The Presence of Reactive Cefaclor Metabolites
A.C. Tschen MSc, J.A. Wijsman MSc, D.M. Matsui MD and M.J. Rieder MD, PhD
Clin Pharmacol Ther 65: 137; doi:10.1016/S0009-9236(99)80081-2
Effects of Vehicle on The Efficacy of Activated Charcoal
T. Tschen BSc, S. Miller, H. Zilberman MD, D. Freeman PhD and M.J. Rieder MD, PhD
Clin Pharmacol Ther 65: 137; doi:10.1016/S0009-9236(99)80082-4
Amethocaine Vs Lidocaine — Prilocaine Local Anaethetic Ointments, for Procedural Pain in Children
R. Bishai MD, M.H. Freedman MD and G. Koren MD
Clin Pharmacol Ther 65: 138; doi:10.1016/S0009-9236(99)80083-6
The Effects of Intrauterine Cocaine Exposure on Neurodevelopment of Adopted Children: The Toronto Adoption Study
I. Nulman MD, J. Rover PhD, R. Greenbaum BSc, M. Loebstein MA, J. Wolpin PhD, P. Pace-Asciak BA and G. Koren MD
Clin Pharmacol Ther 65: 138; doi:10.1016/S0009-9236(99)80084-8
Perinatal Outcome Following Gestational Exposure to Antidepressants; Separating The Effects of Depression, Pharmacotherapy and Other Confounders
I. Nulman MD, J. Wolpin PhD, J. Theis MD, D. Stewart MD and G. Koren MD
Clin Pharmacol Ther 65: 138; doi:10.1016/S0009-9236(99)80085-X
Population Pharmacokinetics of Methylphenidate
R.I. Shader, J.S. Harmatz, J.R. Oesterheld, D.X. Parmalee, F.R. Sallee and D.J. Greenblatt
Clin Pharmacol Ther 65: 138; doi:10.1016/S0009-9236(99)80086-1
Cytochrome P450 in Normal Pediatric Vs Adult Human Liver
M.V. Relling PharmD, P.L. Harrison MS and W.E. Evans PharmD
Clin Pharmacol Ther 65: 139; doi:10.1016/S0009-9236(99)80087-3
Accuracy of Cytochrome P4502D6 (CYP2D6): Phenotype Assignment From Genotyping Data
A. Gaedigk PhD, R.R. Gotschall MS, N.S. Forbes BS, S.D. Simon PhD and J.S. Leeder PharmD, PhD
Clin Pharmacol Ther 65: 139; doi:10.1016/S0009-9236(99)80088-5
Pharmacokinetics (PK) of Rifapentine (RIF) in Adolescents
J.D. Marshall, R.E. Kauffman, A. Keung, K.M. Johnson, S. Abdel-Rahman and G.L. Kearns
Clin Pharmacol Ther 65: 139; doi:10.1016/S0009-9236(99)80089-7
The Pharmacokinetics of Multihance in Pediatric Subjects, A Population Approach
B.E. Davies, K. Kozlowski, J.R. Parker, L. Krinsky, H. Hutman MD and N. LaFrance MD
Clin Pharmacol Ther 65: 139; doi:10.1016/S0009-9236(99)80090-3
Pharmacokinetics (PK) of Pleconaril (PLEC) in Neonates
G.L. Kearns, J.S. Bradley, S. Abdel-Rahman, R.F. Jacobs and the PPRU Network
Clin Pharmacol Ther 65: 140; doi:10.1016/S0009-9236(99)80091-5
CYP2C9 Genotype and Ibuprofen (IBU) Pharmacokinetics (PK) in Cystic Fibrosis (CF)
D.J. Murry, G.L. Kearns, C. Oermann, A. Gaedigk, M. Sockrider, D.K. Seilheimer and J.S. Leeder
Clin Pharmacol Ther 65: 140; doi:10.1016/S0009-9236(99)80092-7
Population pharmacokinetics in pediatric patients using bayesian approaches with informative prior distributions based on adults.
W.R. Gillespie PhD, K.-C. Khoo MS and PPRU Network
Clin Pharmacol Ther 65: 140; doi:10.1016/S0009-9236(99)80093-9
Limited sampling design in clinical pediatric population pharmacokinetic (PPK) studies.
He Sun PhD, Frank Pelsor PharmD and John Lazor PharmD, OCPB, FDA
Clin Pharmacol Ther 65: 140; doi:10.1016/S0009-9236(99)80094-0
Fluoxetine and its effects on the nursing infant: A prospective cohort study.
M.E. Moretti MSc, A. Sharma, B. Bar-Oz MD, G. Koren MD and S. Ito MD
Clin Pharmacol Ther 65: 141; doi:10.1016/S0009-9236(99)80095-2
Is there a need for bridging studies for development of novel neuroactive drugs?
S.J. Offord PhD
Clin Pharmacol Ther 65: 141; doi:10.1016/S0009-9236(99)80096-4
Capturing the fuzziness in clinical psychopharmacological data.
B.A. Sproule PharmD, C.A. Naranjo MD and D.M. Knoke MA
Clin Pharmacol Ther 65: 141; doi:10.1016/S0009-9236(99)80097-6
Blunted d-amphetamine response in major depressive disorder (MDD).
L.K. Tremblay BSc, C.A. Naranjo MD, U. Busto PharmD and L. Cardenas MD
Clin Pharmacol Ther 65: 141; doi:10.1016/S0009-9236(99)80098-8
In vitro inhibition of CYP2D6 activity by fenfluramine.
K. Marcucci BS, R. Gotschall MS, G.L. Kearns PharmD and J.S. Leeder PharmD, PhD
Clin Pharmacol Ther 65: 142; doi:10.1016/S0009-9236(99)80099-X
Metabolic, pharmacokinetic and pharmacodynamic interactions of triazolam and ketoconazole in rats.
T. Kotegawa MD, B.E. Laurijssens MA and D.J. Greenblatt MD
Clin Pharmacol Ther 65: 142; doi:10.1016/S0009-9236(99)80100-3
Patterns of benzodiazepine (B) use and dependence in Canada.
C. Borgoño BSc, U.E. Busto PharmD and E.M. Sellers MD, PhD
Clin Pharmacol Ther 65: 142; doi:10.1016/S0009-9236(99)80101-5
Ketoconazole differentially inhibits zolpidem and triazolam biotransformation: In vitro mechanism and in vivo consequence.
D.J. Greenblatt, L.L. von Moltke, J.S. Harmatz, B.W. Granda and R.I. Shader
Clin Pharmacol Ther 65: 142; doi:10.1016/S0009-9236(99)80102-7
Haloperidol metabolites inhibit CYP2D6 catalyzed dextromethorphan O-demethylation in vitro.
J.G. Shin MD, PhD, K. Kane and D.A. Flockhart MD, PhD
Clin Pharmacol Ther 65: 143; doi:10.1016/S0009-9236(99)80103-9
Repeated administrations of amisulpride (A) do not modify lithium carbonate (L) pharmacokinetics in healthy volunteers.
S. Chaufour MD, N.G. Borgstein MD, W. Van den Eynde MD, F. Bernard PhD, M. Canal PharmD, I. Zieleniuk MD and J.L. Pinquier MD
Clin Pharmacol Ther 65: 143; doi:10.1016/S0009-9236(99)80104-0
In vivo inhibition of midazolam disposition by ketoconazole and fluoxetine, and comparison to in vitro prediction.
Y.W.F. Lam PharmD, L. Ereshefsky PharmD, C. Alfaro PharmD and Michael Miller MD
Clin Pharmacol Ther 65: 143; doi:10.1016/S0009-9236(99)80105-2
Multiple site interaction of triazolam and ketoconazole in mice: Role of P-glycoprotein.
L.L. von Moltke, B.W. Granda, J.M. Grassi and D.J. Greenblatt
Clin Pharmacol Ther 65: 143; doi:10.1016/S0009-9236(99)80106-4
Meta-chloro-phenylpiperazine (mCPP): P450-3A-dependent formation from nefazodone and trazodone; P450-2D6-dependent clearance.
L.L. von Moltke, A. Zalma, B.W. Granda, L.M. Grassi, R.I. Shader and D.J. Greenblatt
Clin Pharmacol Ther 65: 144; doi:10.1016/S0009-9236(99)80107-6
Assessment of bioequivalence of inhaled products via in-vivo deposition data.
K.F. Rooney PhD, S.P. Newman PhD and I.R. Wilding PhD
Clin Pharmacol Ther 65: 144; doi:10.1016/S0009-9236(99)80108-8
Azithromycin-theophylline inhibition-induction interaction.
P.T. Pollak MD, PhD and D.M. MacNeil MD
Clin Pharmacol Ther 65: 144; doi:10.1016/S0009-9236(99)80109-X
2-adrenergic receptor (2AR) polymorphism affects albuterol concentration (Cp)-response relationship in asthmatics.
J.A. Johnson PharmD, D.B. Thomason PhD, M.H.N. Mohamed PharmD, T.H. Self PharmD, L.V. Eberle MD and J.J. Lima PharmD
Clin Pharmacol Ther 65: 144; doi:10.1016/S0009-9236(99)80110-6
Disposition kinetics and effects of menthol.
A. Gelal MD, P. Jacob PhD, L. Yu BS and N.L. Benowitz MD
Clin Pharmacol Ther 65: 145; doi:10.1016/S0009-9236(99)80111-8
Inhibition of nicotine's metabolism: A potential new treatment for tobacco dependence.
R.F. Tyndale PhD, Y. Li PhD, H.L. Kaplan PhD and E.M. Sellers MD, PhD
Clin Pharmacol Ther 65: 145; doi:10.1016/S0009-9236(99)80112-X
Cognitive performance is not impaired by carbon monoxide exposure comparable to usual cigarette smoking.
S. Gourlay MBBS, PhD and N. Benowitz MD
Clin Pharmacol Ther 65: 145; doi:10.1016/S0009-9236(99)80113-1
First randomized controlled trial (RCT) of methadone (M), levomethadyl acetate (LAAM) and buprenorphine (BUP) in opioid dependence treatment.
R.E. Johnson PharmD, M.A. Chutuape PhD, E.C. Strain MD, S.L. Walsh PhD, M.L. Stitzer PhD and G.E. Bigelow PhD
Clin Pharmacol Ther 65: 145; doi:10.1016/S0009-9236(99)80114-3
Ecopipam (SCH 39166), A D1 antagonist, on acute effects of cocaine.
M.K. Romach MD, K. Kampman, P. Glue MD, PhD, G.R. Somer MA, H.L. Kaplan PhD, J.C. Spears MD, S. Poole, L. Clarke RN, V. Coffin, C.P. O'Brien MD, PhD and E.M. Sellers MD, PhD
Clin Pharmacol Ther 65: 146; doi:10.1016/S0009-9236(99)80115-5
Regulation of human particulate guanylyl cyclase gene expression by the homeodomain protein, cdx-2.
J. Park BS, S. Schulz PhD and S.A. Waldman MD, PhD
Clin Pharmacol Ther 65: 146; doi:10.1016/S0009-9236(99)80116-7
Inhibition of nuclear factor kappa B (NF-kB) by aminosalicylates: Structure activity relationships.
L. Egan MB, W. Sandborn MD, D. Mays PhD, M. Pike, M. Bell, C. Huntoon, D. McKean PhD and J. Lipsky MD
Clin Pharmacol Ther 65: 146; doi:10.1016/S0009-9236(99)80117-9
Histamine N-methyltransferase (HNMT) pharmacogenetics: Association of the C314T genetic polymorphism with allergic asthma.
L. Yan, R.E. Galinsky, S.B. Liggett and R.M. Weinshilboum
Clin Pharmacol Ther 65: 146; doi:10.1016/S0009-9236(99)80118-0
Histamine response and local cooling in the human skin.
M. Grossmann MD, M.J. Jamieson MD and W. Kirch MD, PhD
Clin Pharmacol Ther 65: 147; doi:10.1016/S0009-9236(99)80119-2
Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in mild asthmatics.
P. Zia-Amirhosseini PhD, C. Walls MSc, B. Patel PhD, H. Cowley MD, E. Minthorn BS and C.S. Hottenstein BS
Clin Pharmacol Ther 65: 147; doi:10.1016/S0009-9236(99)80120-9
Risk factors for QTc interval prolongation induced by intravenous haloperidol.
J.E. Tisdale PharmD, N.B. Amin PharmD, N. Sharma MD and H. Rosman MD
Clin Pharmacol Ther 65: 147; doi:10.1016/S0009-9236(99)80121-0
Confidence interval (CI) calculations for within-patient correlations—ECG p-wave detection.
D.A. Spyker, M.L. Kroen, G. Gray CDRH, FDA, Y. Wang and B. Flynn
Clin Pharmacol Ther 65: 148; doi:10.1016/S0009-9236(99)80122-2
Efficacy of CS-747, a new potent antiplatelet agent.
T. Hirota PhD, H. Sugii, F. Asai PhD, K. Kawabata, T. Inoue, R. Iwamura, S. Freestone MD and J. Dickson MB
Clin Pharmacol Ther 65: 148; doi:10.1016/S0009-9236(99)80123-4
Pharmacokinetic/pharmacodynamic characteristics following nighttime dosing of verapamil-ER.
J.G. Devane PhD and J. Butler PhD
Clin Pharmacol Ther 65: 148; doi:10.1016/S0009-9236(99)80124-6
Effect of fluoxetine on carvedilol stereo-specific pharmacokinetics in patients with heart failure.
D.W. Graff PharmD, K.M. Williamson PharmD, J.A. Pieper PharmD, K.F. Adams Jr. MD, S. Smith PhD, S.W. Carson PharmD and J.H. Patterson PharmD
Clin Pharmacol Ther 65: 148; doi:10.1016/S0009-9236(99)80125-8
In vivo inhibitory effect of phenytoin (P) on losartan (L) disposition.
T.L. Allen PharmD, J.A. Pieper PharmD, J.H. Patterson PharmD, D.W. Graff PharmD, J.E. Rodgers PharmD, K.J. Parnell PharmD and R. Greenwood MD
Clin Pharmacol Ther 65: 149; doi:10.1016/S0009-9236(99)80126-X
Oral but not intravenous (IV) diltiazem impairs lovastatin clearance.
D.R. Jones PhD, N.E. Azie MD, A. Masica BA, D.C. Brater MD and S.D. Hall PhD
Clin Pharmacol Ther 65: 149; doi:10.1016/S0009-9236(99)80127-1
Grapefruit juice (GFJ) has a small effect on lovastatin plasma HMG-CoA reductase inhibitor (HMGRI) profiles.
J.D. Rogers PhD, J.M. Vega MD, J. Zhao PhD, L. Liu MS, R.D. Amin BA, K. Gagliano BS, MEd, M. Stepanavage MS, M.F. Wilson MD and R.A. Blum PharmD
Clin Pharmacol Ther 65: 149; doi:10.1016/S0009-9236(99)80128-3
CYP1A2 4-hydroxylates propranolol.
J.A. Johnson PharmD and M.V. Relling PharmD
Clin Pharmacol Ther 65: 149; doi:10.1016/S0009-9236(99)80129-5
Beta-receptor occupancy after chronic bisoprolol dosing.
C.J. Rosebraugh MD, J.T. Barbey MD, C. Funck-Brentano MD and S.U. Yasuda MS, PharmD
Clin Pharmacol Ther 65: 150; doi:10.1016/S0009-9236(99)80130-1
Adrenergic responses in post-menopausal women: No evidence of modulation by estrogen.
G.G. Sofowora MBChB, I. Singh MD, C.M. Stein MBChB, H.B. He PharmD and A.J.J. Wood MBChB
Clin Pharmacol Ther 65: 150; doi:10.1016/S0009-9236(99)80131-3
Limited availability of no impairs hemodynamic efficacy of the new organic nitrate SP/W-5186 in man.
D. Trenk PhD, M. Hinder MD, E. Fung, E. Stengele MD, R. Bonn PhD and E. Jähnchen MD
Clin Pharmacol Ther 65: 150; doi:10.1016/S0009-9236(99)80132-5
Concentration-effect relationships of the new orally active RGD-type glycoprotein IIb/IIIa-Antagonist S1197 in man.
D. Trenk PhD, E. Stengele MD, R. Adler MD, M. Just MD, D. Brockmeier PhD, M. Seibert-Grafe MD and E. Jähnchen MD
Clin Pharmacol Ther 65: 150; doi:10.1016/S0009-9236(99)80133-7
PK and PD of escalating, single IV doses of a synthetic allosteric hemoglobin (Hb) modifier, RSR13, in patients with stable effort angina.
J. Venitz MD, PhD, J.F. Liard MD and J. Hackman PhD
Clin Pharmacol Ther 65: 151; doi:10.1016/S0009-9236(99)80134-9
Effect of clemastine on the ECG in healthy volunteers.
S.U. Yasuda MS, PharmD, M. Ndey MD and R.L. Woosley MD, PhD
Clin Pharmacol Ther 65: 151; doi:10.1016/S0009-9236(99)80135-0
PK-PD relationship of the effects of argatroban on haemostasis in healthy young volunteers.
D. Garrigou PhD, C. Dubruc PhD, C. Thuillez MD, L. Bergougnan MD and J.P. Thenot PhD
Clin Pharmacol Ther 65: 151; doi:10.1016/S0009-9236(99)80136-2
Impact of clinical pharmacist-based intervention on outcomes in CHF.
Aileen B. Luzier PharmD, Brad Robison MD, Stephen G. Feuerstein, Jerome J. Schentag PharmD and Joseph L. Izzo MD
Clin Pharmacol Ther 65: 151; doi:10.1016/S0009-9236(99)80137-4
The mass balance of buprenorphine in humans.
E. Thomas Everhart PhD, Polly Cheung BS, John Mendelson MD, Robert Upton PhD and Reese T. Jones MD
Clin Pharmacol Ther 65: 152; doi:10.1016/S0009-9236(99)80138-6
Cocaine cue reactivity and fluoxetine treatment outcome in cocaine dependent subjects.
D.S. Harris MD, S.L. Batki MD and S.P. Berger MD
Clin Pharmacol Ther 65: 152; doi:10.1016/S0009-9236(99)80139-8
Characteristics of medical marijuana users.
D.S. Harris MD, R.T. Jones MD and John E. Mendelson MD
Clin Pharmacol Ther 65: 152; doi:10.1016/S0009-9236(99)80140-4
Neonatal hair benzoylegonine (BZE) levels: A predictor for neurodevelopment (ND) at 3 years in children exposed to cocaine in utero (CECU).
L.D. Katikaneni MD, F.R. Sallee, M. Macias, G. Sethuraman and T. Hulsey
Clin Pharmacol Ther 65: 152; doi:10.1016/S0009-9236(99)80141-6
Urine and sweat monitoring of illicit opiate use.
K.L. Preston PhD, M.A. Huestis PhD, C.J. Wong and E.J. Cone PhD
Clin Pharmacol Ther 65: 153; doi:10.1016/S0009-9236(99)80142-8
Monoclonal antibodies as long-term antagonists of phencyclidine (PCP).
J.S. Hardin PhD, G.R. Wenger PhD, W.D. Wessinger PhD and S.M. Owens PhD
Clin Pharmacol Ther 65: 153; doi:10.1016/S0009-9236(99)80143-X
Inhibition of CYP2A6 decreases smoking.
E.M. Sellers MD, PhD, H.L. Kaplan PhD, M.K. Romach MD and R.F. Tyndale PhD
Clin Pharmacol Ther 65: 153; doi:10.1016/S0009-9236(99)80144-1
Capsaicin increases the lethality of cocaine.
John Mendelson MD, Brian Tolliver PhD, Kevin Delucchi PhD and Paul Berger MD
Clin Pharmacol Ther 65: 153; doi:10.1016/S0009-9236(99)80145-3
Dose proportionality of 4, 8, 16 and 32 mg sublingual buprenorphine solutions.
John Mendelson MD, Robert Upton PhD, Emil Lin PhD, Susette Welm MA and Reese T. Jones MD
Clin Pharmacol Ther 65: 154; doi:10.1016/S0009-9236(99)80146-5
Nicotine-mecamylamine interaction.
Shoshana Zevin MD, Peyton Jacob III PhD and Neal L. Benowitz MD
Clin Pharmacol Ther 65: 154; doi:10.1016/S0009-9236(99)80147-7
Carbon monoxide, cigarette smoking and CYP2E1 activity.
Neal L. Benowitz MD, Peyton Jacob III PhD, S. Saunders MD and S. Gourlay MB, PhD
Clin Pharmacol Ther 65: 154; doi:10.1016/S0009-9236(99)80148-9
In vitro inhibition of laam metabolism by HIV protease inhibitors.
B. Davit PhD, S. Cherstniakova PhD, J. Mojsiak MD and L. Cantilena MD, PhD
Clin Pharmacol Ther 65: 154; doi:10.1016/S0009-9236(99)80149-0
Catalysis of a disulfiram metabolite, S-methyl-N,N-diethyldithiocarbamate, by CYP450 and FMO3 in human liver microsomes.
M.G. Pike BA, Y.N. Martin, D.C. Mays PhD and J.J. Lipsky MD
Clin Pharmacol Ther 65: 155; doi:10.1016/S0009-9236(99)80150-7
Adenosine receptor antagonists inhibit the expression of opiate-inducedlocomotor sensitization in mice.
G.B. Kaplan and S.P. Weisberg
Clin Pharmacol Ther 65: 155; doi:10.1016/S0009-9236(99)80151-9
Modeling nicotine arterial-venous differences.
M. Pitsiu PhD, J.M. Gries PharmD, N.L. Benowitz MD, S.G. Gourlay FRACP, PhD and D. Verotta PhD
Clin Pharmacol Ther 65: 155; doi:10.1016/S0009-9236(99)80152-0
Phencyclidine (PCP) distribution in rats: Unique time profiles of brain and testis accumulation.
W.B. Gentry MD, J.W. Proksch and S.M. Owens PhD
Clin Pharmacol Ther 65: 155; doi:10.1016/S0009-9236(99)80153-2
Increases in transaminases on placebo during phase I trials.
P. Rosenzweig MD, N. Miget PhD, S. Brohier PhD and I. Zieleniuk MD
Clin Pharmacol Ther 65: 156; doi:10.1016/S0009-9236(99)80154-4
Comparative effects on cardiac repolarization of cisapride, erythromycin, tegaserod and its metabolite in isolated rabbit hearts.
M.-D. Drici MD, PhD, S. Ebert PhD, W.-X Wang MD and R.L. Woosley MD, PhD
Clin Pharmacol Ther 65: 156; doi:10.1016/S0009-9236(99)80155-6
Biomarkers of acetaminophen (APAP) toxicity in pediatric patients.
L. James, J. Wilson, R. Simar, H. Farrar, G. Kearns, J. Hinson, N. Pumford and PPRU Network, NICHD.
Clin Pharmacol Ther 65: 156; doi:10.1016/S0009-9236(99)80156-8
Antigenic biomarker identification of acetaminophen (APAP) hepatotoxicity (HT) in children.
L. James MD, H. Farrar, J. Sullivan, G. Kearns, J. Hinson, N. Pumford and PPRU Network, NICHD.
Clin Pharmacol Ther 65: 156; doi:10.1016/S0009-9236(99)80157-X
Troglitazone induces CYP3A4 in cultured human hepatocytes.
E.L. LeCluyse PhD, J. Sahi PhD, M. Sinz PhD, T. Woolf PhD, R. Hawke PhD, G. Hamilton PhD, L.J. Lesko PhD and S.-M. Huang PhD
Clin Pharmacol Ther 65: 157; doi:10.1016/S0009-9236(99)80158-1
Classic antihistamines inhibit metoprololhydroxylation in vitro.
B. Hamelin PharmD, S. Pilote MSc and J. Turgeon PhD
Clin Pharmacol Ther 65: 157; doi:10.1016/S0009-9236(99)80159-3
Metoprolol/diphenhydramine interaction in men with high and low CYP2D6 activity.
B.A. Hamelin PharmD, J. Méthot MSc, S. Pilote MSc, P. Poirier MD, J. Dumesnil MD and J. Turgeon PhD
Clin Pharmacol Ther 65: 157; doi:10.1016/S0009-9236(99)80160-X
An extensive evaluation of spot urinary 6-Beta hydroxycortisol (6OHC) as a biological marker for CYP3A4 induction.
J.O. Tran PharmD, S.J. Kovasc PharmD, T.S. McIntosh MS, H.M. Davis PhD and D.E. Martin PharmD
Clin Pharmacol Ther 65: 157; doi:10.1016/S0009-9236(99)80161-1
Stereoselective monitoring of 
verapamil treatment of women with bipolar disorder.
J.M. Perel PhD, K.L. Wisner MD, G. Rudolph MS and K. Peindl PhD
Clin Pharmacol Ther 65: 158; doi:10.1016/S0009-9236(99)80162-3
Method for determining the hurst exponent of a fractal time series and its applications to EKG signal analysis.
P.B. DePetrillo MD and U. Ruttimann PhD
Clin Pharmacol Ther 65: 158; doi:10.1016/S0009-9236(99)80163-5
Alcohol consumption is associated with decreased cardiac signal complexity.
P.B. DePetrillo MD, K.V. White MS, M. Liu, D. Hommer MD and D. Goldman MD
Clin Pharmacol Ther 65: 158; doi:10.1016/S0009-9236(99)80164-7
Alterations of intracellular glutathione levels in PBMCS of HIV patients during sulfonamide therapy.
D. Schiedel BSc, J. Tucker PhD, J. Wijsman MSc and M.J. Rieder MD, PhD
Clin Pharmacol Ther 65: 158; doi:10.1016/S0009-9236(99)80165-9
Disruption of mitochondrial function by the hydroxylamine metabolite of sulfamethoxazole.
J.A. Wijsman MSc and M.J. Rieder MD, PhD
Clin Pharmacol Ther 65: 159; doi:10.1016/S0009-9236(99)80166-0
Sirolimus oral bioavailability increases ten-fold with concomitant ketoconazole.
L.C. Floren PharmD, U. Christians MD, PhD, J.J. Zimmerman PhD, L. Neefe MD, R. Schorer PhD, D. Rushworth BS, D. Harper BS, J. Renz MD and L.Z. Benet PhD
Clin Pharmacol Ther 65: 159; doi:10.1016/S0009-9236(99)80167-2
Reduction of plasma mycophenolic acid (MPA) and its glucuronide (MPAG) concentrations with antibiotic treatment.
O.J. Naderer PharmD, R.E. Dupuis PharmD, K. Wiwattanawongsa MS, B.J. Campbell, S.G. Hege MS, P.C. Smith PhD and M.W. Johnson MD
Clin Pharmacol Ther 65: 159; doi:10.1016/S0009-9236(99)80168-4
Red wine (RW) effects on cyclosporine (CyA) pharmacokinetics.
S.M. Tsunoda PharmD, R.Z. Harris PhD, R.L. Velez PharmD, A. Warshaw PA-C and R.B. Freeman MD
Clin Pharmacol Ther 65: 159; doi:10.1016/S0009-9236(99)80169-6
Cyclosporine pharmacokinetics and pharmacodynamics in African-Americans (AA) and Caucasians (C).
C.M. Stein MD, A.J. Sadeque PhD, C. Wandel MD, R.B. Kim MD, J.J. Murray MD and A.J.J. Wood MD
Clin Pharmacol Ther 65: 160; doi:10.1016/S0009-9236(99)80170-2
A rapid pharmacodynamic measure to determine interindividual variability in response to cyclosporine.
C.M. Stein MD, J.J. Murray MD and A.J.J. Wood MD
Clin Pharmacol Ther 65: 160; doi:10.1016/S0009-9236(99)80171-4
A pharmacokinetic trial of thymosin 1 (T1) in healthy volunteers.
G. Merritt PharmD and C.W. Tuthill PhD
Clin Pharmacol Ther 65: 160; doi:10.1016/S0009-9236(99)80172-6
Halofantrine stereoselective clearance and QT prolongation.
D.R. Abernethy MD, PhD, D. Wesche MD, PhD, J.T. Barbey MD, C. Ohrt MD, S. Mohanty, J. Pezzullo PhD and B. Schuster MD, PhD
Clin Pharmacol Ther 65: 160; doi:10.1016/S0009-9236(99)80173-8
Pharmacokinetic strategies for concentration-targeted therapy with zidovudine (ZDV) lamivudine (3TC), and indinavir (IDV).
C.V. Fletcher PharmD, T.N. Kakuda PharmD, L.M. Page PharmD, E.P. Acosta PharmD, R.C. Brundage PhD, P.L. Anderson PharmD, K. Henry MD and T. Schacker MD
Clin Pharmacol Ther 65: 161; doi:10.1016/S0009-9236(99)80174-X
Penetration of rifabutin (R) into cerebrospinal fluid (CSF) of ventriculostomy patients.
K.W. Garey PharmD, A.D. Killian PharmD, P.K. Narang PhD, M. Luer PharmD, M. Dujovny MD, L.H. Danziger PharmD and K.A. Rodvold PharmD
Clin Pharmacol Ther 65: 161; doi:10.1016/S0009-9236(99)80175-1
Comparative bioavailability of loracarbef chewable tablet vs oral suspension in children.
D.L. Blowey MD, S.M. Abdel-Rahman PharmD, R.E. Kauffman MD and G.L. Kearns PharmD
Clin Pharmacol Ther 65: 161; doi:10.1016/S0009-9236(99)80176-3
Pharmacokinetics (PK) of stavudine (d4T) in cerebrospinal fluid (CSF) of HIV infected subjects using sparse sampling.
S.E. Bellibas MD, R.W. Price MD, L. Sheiner MD, S. Staprans PhD, R.E. Kates PhD and F. Aweeka PharmD
Clin Pharmacol Ther 65: 161; doi:10.1016/S0009-9236(99)80177-5
The influence of reduced liver blood flow (LBF) on the pharmacokinetics (PK) of (LBF) on the pharmacokinetics (PK) of recombinant tissue factor pathway inhibitor (rTFPI).
M. Kemme MD, J. Burggraaf MD, PhD, A. Karim PhD, N. Singh PhD, A. Childs BA, R. Braeckman PhD, R. Schoemaker MSc and A. Cohen MD, PhD
Clin Pharmacol Ther 65: 162; doi:10.1016/S0009-9236(99)80178-7
Quantitation of intracellular triphosphate of -L-2', 3'-dideoxy-5'-fluoro-3'-thiacytidine (FTC) in peripheral blood mononuclear cells from HIV-infected patients.
G. Valette PhD, A. Darque PharmD, L.H. Wang PhD, J. Delehanty PhD, L. Hulett, B. McCreedy PhD, F. Rousseau MD, J.P. Sommadossi PhD and X.J. Zhou PhD
Clin Pharmacol Ther 65: 162; doi:10.1016/S0009-9236(99)80179-9
A population PK model for vancomycin in pediatric patients and its predictive value in a naive population.
P. Lamarre BPharm and M.P. Ducharme PharmD
Clin Pharmacol Ther 65: 162; doi:10.1016/S0009-9236(99)80180-5
Population pharmacokinetics of linezolid in subjects with a range of renal function.
M. Brier PhD, D. Stalker PhD, G. Aronoff MD, D. Batts MD, K. Ryan BS, M. O'Grady BS and N. Hopkins PhD
Clin Pharmacol Ther 65: 162; doi:10.1016/S0009-9236(99)80181-7
A population pharmacokinetic (PPK) analysis of dalfopristin/quinupristin (D/Q), a new injectable antibiotic.
R. Bruno, N. Vivier, P. Baille, S. Rouault, G. Montay and G.H. Talbot
Clin Pharmacol Ther 65: 163; doi:10.1016/S0009-9236(99)80182-9
A new model for bacterial growth & drug effects.
A. Forrest, J.M. Hyatt, M.R. Turnak, C.H. Ballow, D.J. Stalker, I.R. Welshman and J.J. Schentag
Clin Pharmacol Ther 65: 163; doi:10.1016/S0009-9236(99)80183-0
MK-0966, a cyclooxygenase-2 (COX-2) specific inhibitor, had no effect on the anti-platelet activity of low-dose aspirin (ASA) measured by serum thromboxane B2 (TXB2) production and platelet aggregation.
H.E. Greenberg MD, L.P. Gillen MS, E.P. Dorval RN, L. Wildonger BS, P. Larson BS, M. Huntington MS, P. Wong MS, K. Gottesdiener MD and S.A. Waldman MD
Clin Pharmacol Ther 65: 163; doi:10.1016/S0009-9236(99)80184-2
Chiral inversion of ibuprofen in children with cystic fibrosis.
J.O. Dong BS, B.J. Glasscock, C.S. Scott PharmD, G.Z. Retsch-Bogart MD and P.C. Smith PhD
Clin Pharmacol Ther 65: 163; doi:10.1016/S0009-9236(99)80185-4
Flurbiprofen metabolism by chimeric P450 2C9/19 enzymes.
J.M. Hutzler BS, A.E. Rettie PhD, R.L. Haining PhD and T.S. Tracy PhD
Clin Pharmacol Ther 65: 164; doi:10.1016/S0009-9236(99)80186-6
Demonstration of specific COX-2 inhibition by MK-966 in humans with supratherapeutic doses.
A. Van Hecken PhD, M. Depré PhD, E. Ehrich MD, I. De Lepeleire PharmD, D. Hilliard BSc, A. Porras PhD, P. Wong MSc, A. Buntinx PharmD, B.J. Gertz MD and P.J. De Schepper MD
Clin Pharmacol Ther 65: 164; doi:10.1016/S0009-9236(99)80187-8
Model optimization via "Lateral validation", for purposes of clinical trial simulation.
J.V.S. Gobburu PhD, N.H.G. Holford FRACP, H.C. Ko PhD, C.C. Peck MD and G.G. Liversidge PhD
Clin Pharmacol Ther 65: 164; doi:10.1016/S0009-9236(99)80188-X
Prostaglandin (PG) E2 and PGD2 are formed in significant quantities via the isoprostane pathway in vivo.
Jason D. Morrow MD and Jackson Roberts MD
Clin Pharmacol Ther 65: 164; doi:10.1016/S0009-9236(99)80189-1
Cerebrospinal fluid levels of F2-isoprostanes in patients with neurodegenerative diseases.
Jason D. Morrow MD, L. Jackson Roberts MD, Thomas J. Montine MD, M. Flint Beal MD, Merit E. Cudkowicz MD and Heather O'Donnell MD
Clin Pharmacol Ther 65: 165; doi:10.1016/S0009-9236(99)80190-8
Rapid development of tolerance to dipyridamole associated headaches.
J.G.W. Theis MD, G. Deichsel PhD, R. Brickl PhD and S. Marshall
Clin Pharmacol Ther 65: 165; doi:10.1016/S0009-9236(99)80191-X
Inhibition of metabolism of mephenytoin enantiomers by sulfaphenazole and fluconazole.
A. Adedovin PhD and C.B. Bolcato
Clin Pharmacol Ther 65: 165; doi:10.1016/S0009-9236(99)80192-1
Pharmacokinetics, Pharmacodynamics and Tolerance of SLV 307 After Single Oral Administration in Healthy Male Volunteers
M.H. de Vries PhD and J. Udo de Haes MSc
Clin Pharmacol Ther 65: 165; doi:10.1016/S0009-9236(99)80193-3
The Effect of Glycerol Trinirate on Cerebral Circulation and Quantitative EEG
M. Siepmann and W. Kirch
Clin Pharmacol Ther 65: 166; doi:10.1016/S0009-9236(99)80194-5
Meta-Analysis of The Exposure/Efficacy Relationship for Sumatriptan Nasal Spray
O. Petricoul and E. Fuseau
Clin Pharmacol Ther 65: 166; doi:10.1016/S0009-9236(99)80195-7
The Gene Polymorphism of Angiotensinconverting Enzyme in Patients With Ischemic Stroke
J.-T Kwon MD, H.-K Kim MD, S. Chai MSc, D.-G. Yang MD, C.-O. Bang MD, H.-K. Park MD, H.-K. Shin MD, K.-B Seong MD and D.-R. Sohn MD
Clin Pharmacol Ther 65: 166; doi:10.1016/S0009-9236(99)80196-9
Dextromethorphan O-Demethylation Genetic Polymorphism in A Hybrid South American Population
F. Estevez-Carrizo MD, M. Giusti MD and S. Parrillo MD
Clin Pharmacol Ther 65: 166; doi:10.1016/S0009-9236(99)80197-0
Poor Correlation Between 24 hr Urinary 6-Hydroxy Cortisol: Cortisol Molar Ratios (CMR) and Plasma Midazolam Clearance (MDZ CL) as Measures of Hepatic CYP3A Activity
S. Karl Gotzkowsky PharmD, A.D.M. Kashuba PharmD, William Hall BS, R.W. Kulaway BS, D.J. Beck BS, M.L. Rocci Jr PhD, A.N. Nafziger MD and J.S. Bertino Jr. PharmD
Clin Pharmacol Ther 65: 167; doi:10.1016/S0009-9236(99)80198-2
Evaluation of Phenytoin Dosage Regimen Based On The Genetic Test of CYP2C Subfamily
Y. Hashimoto PhD, U. Uwai BS, A. Odani BS, H. Hattori MD, PhD and K. Iniu PhD
Clin Pharmacol Ther 65: 167; doi:10.1016/S0009-9236(99)80199-4
A PK/PD Model for Perflubron Emulsion (PFOB) in Cardiopulmonary Bypass (CPB) Patients
W.J. Bachman, W. Cheung and P. Keipert
Clin Pharmacol Ther 65: 167; doi:10.1016/S0009-9236(99)80200-8
Tolerability and Pharmacokinetics of Fixed Doses of Buspirone Administered Transdermally to Healthy Subjects
I.E. Fulmor BS, O.J. Szylleyko PhD, G.D. Kollia PhD, N.F. Ford MD, PhD and D.E. Salazar PhD
Clin Pharmacol Ther 65: 167; doi:10.1016/S0009-9236(99)80201-X
Single and Multiple Dose Pharmacokinetics of Transdermal Buspirone in Subjects with Hepatic Cirrhosis Compared to Healthy Subjects
R.J. Noveck MD, PhD, D.E. Salazar PhD, I.E. Fulmor, G.D. Kollia PhD, R. Dockens PhD and N.F. Ford MD, PhD
Clin Pharmacol Ther 65: 168; doi:10.1016/S0009-9236(99)80202-1
The Comparative Pharmacokinetics of Zaleplon and Zolpidem
D.R. Drover MD, H.J.M. Lemmens MD, S. Naidu MS, W.H. Cevallos PhD, P. Martin MD and D. Stanski MD
Clin Pharmacol Ther 65: 168; doi:10.1016/S0009-9236(99)80203-3
Novel PK/PD Model Permits Estimation of In-Vivo Muscarinic-Receptor (m-R) Subtype Affinities for Scopolamine (SCP)
S.M. Learned-Coughlin PharmD and J. Venitz MD, PhD
Clin Pharmacol Ther 65: 168; doi:10.1016/S0009-9236(99)80204-5
Pharmacokinetic Modeling of Alcohol Following IV Infusion to Men and Women
S.E. Shoaf PhD, J. Wan MD, R. White RN and D.T. George MD
Clin Pharmacol Ther 65: 168; doi:10.1016/S0009-9236(99)80205-7
Levodopa PK-PD-Analysis in Relation to [18F]F-Dopa-PET in Patients With Parkinsons Disease
S. Harder MD, M. Dietz MD, K. Leenders MD and H. Baas MD
Clin Pharmacol Ther 65: 169; doi:10.1016/S0009-9236(99)80206-9
Utility of Cholinesterase Inhibition in The PK PD, and BA Studies of Anti-Cholinesterases (Anti-AChE)
S. Al-Habet PhD, R. Baweja PhD and E. Mishina PhD
Clin Pharmacol Ther 65: 169; doi:10.1016/S0009-9236(99)80207-0
Orthostasis and Platelet Aggregation Before and After Nefazodone
M. Golding MD, M. Kotlyar PharmD, E. Brewer PharmD and S.W. Carson PharmD
Clin Pharmacol Ther 65: 169; doi:10.1016/S0009-9236(99)80208-2
Cost-Benefit Analysis of Cholinesterase Inhibitors (ChEI) in Alzheimer's Disease (AD)
K.L. Lanctôt PhD, P.I. Oh MD, N. Risebrough BA and N. Herrmann MD
Clin Pharmacol Ther 65: 169; doi:10.1016/S0009-9236(99)80209-4
Hypnotic Use in The Elderly: Perceived Effectiveness, Tolerance and Toxicity
U.E. Busto PharmD, B.A. Sproule PharmD, K. Knight and N. Herrmann MD
Clin Pharmacol Ther 65: 170; doi:10.1016/S0009-9236(99)80210-0
Pharmacokinetic (PK) and Pharmacodynamic (PD) Interaction Between Nefazadone (NEF) and Terfenadine (TER) But Not NEF and Loratidine (LOR)
D.R. Abernethy MD, PhD, J. Barbey MD, J. Franc PhD, I. Ferreira PhD, N. Ford MD, PhD and D.E. Salazar PhD
Clin Pharmacol Ther 65: 170; doi:10.1016/S0009-9236(99)80211-2
CYP2D6 Allele Frequencies in African Americans: Phenotype Concordance With Dextromethorphan (DM)
N.S. Forbes BS, L.D. Bradford PhD, R.R. Gotschall MS, J.S. Leeder PharmD, PhD and A. Gaedigk PhD
Clin Pharmacol Ther 65: 170; doi:10.1016/S0009-9236(99)80212-4
Dextromethorphan (DM) N-Demethylation (N-D) Does Not Accurately Reflect Hepatic CYP3A Phenotype
A.D.M. Kashuba PharmD, A.N. Nafziger MD, G.L. Kearns PharmD, J.S. Leeder PharmD, PhD, R. Gotschall MS, M.L. Rocci Jr PhD, R.W. Kulawy BS, D.J. Beck BS and J.S. Bertino Jr. PharmD
Clin Pharmacol Ther 65: 170; doi:10.1016/S0009-9236(99)80213-6
Venlafaxine-Diphenhydramine Interaction in Subjects With Extensive or Poor CYP2D6 Activity
E. Lessard MSc, M.A. Yessine BSc, B.A. Hamelin PharmD and J. Turgeon PhD
Clin Pharmacol Ther 65: 171; doi:10.1016/S0009-9236(99)80214-8
Pharmacokinetics of Venlafaxine in Subjects With Extensive or Poor CYP2D6 Activity
J. Turgeon PhD, E. Lessard MSc, M.A. Yessine BSc and Bettina A. Hamelin PharmD
Clin Pharmacol Ther 65: 171; doi:10.1016/S0009-9236(99)80215-X
Human Indolethylamine N-Methyl-Transferase (INMT) Pharmacogenetics: CDNA and Gene Cloning and Chromosomal Localization
M.A. Thompson, E. Moon, U.-J. Kim and R.M. Weinshilboum
Clin Pharmacol Ther 65: 171; doi:10.1016/S0009-9236(99)80216-1
Use of Population Pharmacokinetic Modeling to Characterize Intramuscular Pharmacokinetics for Ziprasidone in Schizophrenic Patients
M.U. Shad MD, S.H. Preskorn MD, J. Miceli PhD and K. Wilner PhD
Clin Pharmacol Ther 65: 171; doi:10.1016/S0009-9236(99)80217-3
Ketoconazole (K) Inhibition of Intestinal and Hepatic Cytochrome P450 3A4 (CYP3A4) Activity Using Midazolam (M) As An in Vivo Probe
S.M. Tsunoda PharmD, R.L. Velez PharmD and D.J. Greenblatt MD
Clin Pharmacol Ther 65: 172; doi:10.1016/S0009-9236(99)80218-5
Compliance and Drop-Out Model for Once A Day Regimen in Depressed Patients
P. Girard PhD, E. Van Ganse MD, F. Varret MsC, K. Demyttenaere MD, B. Boulanger PhD and P. Mesters MD
Clin Pharmacol Ther 65: 172; doi:10.1016/S0009-9236(99)80219-7
Efficacy and Safety of Intraarticular Hyaluronic Acid in Osteoarthritis
R.O. Day MD, P.M. Brooks MD, M. Petersen PhD and P. Conaghan MB
Clin Pharmacol Ther 65: 172; doi:10.1016/S0009-9236(99)80220-3
Antipyretic Effect of Celecoxib (C) in Endotoxin Induced Fever
Ramón Vargas MD, F.G. McMahon MD, R. Noveck MD, E. Drower MS, R. Hubbard MD and D. Wallemark PhD
Clin Pharmacol Ther 65: 172; doi:10.1016/S0009-9236(99)80221-5
Influence of Antacids on The Bioavailability (F) of A Specific Cyclooxygenase (COX)-2 Inhibitor, MK-0966 (M) in The Elderly
J. Schwartz, A. Porras, P. Larson, N. Agrawal, C. Gumbs, K. Matthews, E. Woolf, D. Ebel, K. Lasseter and B. Gertz
Clin Pharmacol Ther 65: 173; doi:10.1016/S0009-9236(99)80222-7
Instruments Measuring Clinical Benefit: Who Knows Best, Patient or Instrument?
L.T. Kamboj BSc and M.A.H. Levine MD
Clin Pharmacol Ther 65: 173; doi:10.1016/S0009-9236(99)80223-9
Teaching Clinical Pharmacology and Toxicology (CP&T) To Pediatric Residents: Use of A Jeopardy Game Format
K. Purcell MD, PharmD
Clin Pharmacol Ther 65: 173; doi:10.1016/S0009-9236(99)80224-0
Bayesian Decision Theory for Dose Escalation in Repeat Dose Healthy Volunteer Studies
S.D. Patterson MS, D. Webber MS, N.M.-D. Zariffa MMath, M. Ireson PhD, S. Francis MS and J. Whitehead PhD
Clin Pharmacol Ther 65: 173; doi:10.1016/S0009-9236(99)80225-2
Case Studies, Practical Issues, and Observations on Population and Individual Bioequivalence
N.M.-D. Zariffa MMath, S.D. Patterson MS, D. Boyle PharmD and M. Hyneck PharmD
Clin Pharmacol Ther 65: 174; doi:10.1016/S0009-9236(99)80226-4
Clinical Relevance and Labeling of Food-Effect Bioavailability (FEB) Studies
A. Parekh PhD, A. Barsamian, J.D. Balian MD and L. Lesko PhD
Clin Pharmacol Ther 65: 174; doi:10.1016/S0009-9236(99)80227-6
An Evaluation of The Quality of Herbal Remedy Information Provided by Health Food Store Retailers and Pharmacists
N. Brazier and M.A.H. Levine MD
Clin Pharmacol Ther 65: 174; doi:10.1016/S0009-9236(99)80228-8
The New Drug Approvals of 1996, 1997, & 1998: Drug Development Trends in The User Fee Era
Kenneth I. Kaitin PhD and Elaine M. Healy BA
Clin Pharmacol Ther 65: 174; doi:10.1016/S0009-9236(99)80229-X
CYP1A2 Activity Predicts The Clozapine Steady-State Concentration in Schizophrenic Patients
V. Özdemir MD, PhD, P. Posner MD, E.J. Collins MD, MSc, S.E. Walker MSc, R. Roy RN, W. Walkes RN, B.K. Tang PhD, J.L. Kennedy MD, J. McKenzie and W. Kalow MD
Clin Pharmacol Ther 65: 175; doi:10.1016/S0009-9236(99)80230-6
Human 3'-Phosphoadenosine 5'-Phosphosulfate Synthetase (PAPS-S) Pharmaco-Genetics: Gene Cloning and Chromosomal Localization
D.M. Otterness, S. Mitchell, E. Moon, U.-J. Kim and R.M. Weinshilboum
Clin Pharmacol Ther 65: 175; doi:10.1016/S0009-9236(99)80231-8
Induction of Cytochrome P450 3A4 Activity by Cyclophosphamide, Alone and in Combination With Dexamethasone
C. Lindley PharmD, J. McCune PharmD, R. Hawke PhD, H. Gillenwater MD, W. Petros PharmD and E. LeCluyse PhD
Clin Pharmacol Ther 65: 175; doi:10.1016/S0009-9236(99)80232-X
Apoptosis Induction by The Hydroxylamine of Sulfamethoxazole in Human CD8+ T-Lymphocytes
D.A. Hess BSc, M.E. Sisson DMD, R. Puvi, J.A. Wijsman MSc and M.J. Rieder MD, PhD
Clin Pharmacol Ther 65: 175; doi:10.1016/S0009-9236(99)80233-1
A Randomized, Double Blind, Placebo Controlled Trial of Domperidone in Lactating Mothers of Premature Newborns
D.C. Knoppert MScPhm, P. Forret BScN, IBCLC, M. Angelini BSN, IBCLC and O. Da Silva MD
Clin Pharmacol Ther 65: 176; doi:10.1016/S0009-9236(99)80234-3
Acquistion of Functional CYP2D6 Activity in The First Year of Life
J.S. Leeder PharmD, PhD, A. Gaedigk PhD, R. Gotschall MS, J. Van den Anker MD and G.L. Kearns PharmD
Clin Pharmacol Ther 65: 176; doi:10.1016/S0009-9236(99)80235-5
Children in Research Speak for Themselves
K.M. Johnson RN, P. Colburn RN, S. Hudson LPN, M. Venneman RN and G. Kearns PharmD
Clin Pharmacol Ther 65: 176; doi:10.1016/S0009-9236(99)80236-7
Tolerance of Thiopurine Therapy in Patients With Intermediate Thiopurine S-Methyl Transferase (TPMT) Activity
K. Lewing MD, A. Gaedigk PhD, G. Woods MD, A. Gamis MD, M. Watanabe MD, P. Rothberg PhD, G. Kearns PharmD and J.S. Leeder PharmD, PhD
Clin Pharmacol Ther 65: 176; doi:10.1016/S0009-9236(99)80237-9
Midazolam Sedation for Endoscopy in The Elderly
C. Christe PharmD, J.P. Janssens MD, B. Armenian MD, F. Herrmann MD and N. Vogt MD
Clin Pharmacol Ther 65: 177; doi:10.1016/S0009-9236(99)80238-0
Local Anesthetic Effects of Intradermal RSD921 in Healthy Subjects
A. Doci MD, J. Murugasu FFARCSI, S.B. Ali MB, L.G. Franciosi MSc, T.C. Lee PhD and C.C. Lang MD
Clin Pharmacol Ther 65: 177; doi:10.1016/S0009-9236(99)80239-2
Population Pharmacokinetic Analysis of Flesinoxan
W.J. Bachman, J. Brennan, P. Boon, A. Hage and M. De Vries
Clin Pharmacol Ther 65: 177; doi:10.1016/S0009-9236(99)80240-9
Population Pharmacokinetics of Lidocaine in Korean Adults During General Anesthesia
K.H. Lee MD, K. Park PhD, J.H. Kang MD, H.M. Baek MD, H.K. Roh MD and Y.N. Cha PhD
Clin Pharmacol Ther 65: 177; doi:10.1016/S0009-9236(99)80241-0
The Population Pharmacokinetics of Rapacuronium
H.J.M. Lemmens, D.R. Drover, P.F. White, D.G. Whalley and C.P. Greenberg
Clin Pharmacol Ther 65: 178; doi:10.1016/S0009-9236(99)80242-2
Nicotine impairs endothelium-dependent dilatation in healthy non smokers.
S. Chalon MD, H. Moreno Jr MD, N. Benowitz MD, T.F. Blaschke MD and B.B. Hoffman MD
Clin Pharmacol Ther 65: 178; doi:10.1016/S0009-9236(99)80243-4
Role of a management team in improving ace inhibitor dosing for heart failure.
Brad K. Robison MD, MPH, Suma Gona, Robert Mozersky DO, Aileen Luzier PharmD, Stephen G. Feuerstein, Jerome J. Schentag PharmD and Joseph L. Izzo Jr. MD
Clin Pharmacol Ther 65: 178; doi:10.1016/S0009-9236(99)80244-6
Urinary excretion of nitroprocainamide in subjects with low or high CYP2D6 activity.
E. Lessard MSc, P.M. Bélanger PhD and J. Turgeon PhD
Clin Pharmacol Ther 65: 178; doi:10.1016/S0009-9236(99)80245-8
A population PK (PPK) and logistic regression (LR) analysis of lotrafiban (L) in patients.
D.R. Mould PhD, J.B. Aluri MS, M.C. Chapelsky PharmD, J.G. Granett MD and R. Samuels MS
Clin Pharmacol Ther 65: 179; doi:10.1016/S0009-9236(99)80246-X
Verapamil significantly increases serum concentrations of simvastatin but not pravastatin.
Stephen Donahue MD, Leonard Lachman MD, Jean Norton MS, Tammy Guld BS and Laishun Chen PhD
Clin Pharmacol Ther 65: 179; doi:10.1016/S0009-9236(99)80247-1
Mibefradil significantly increases serum concentrations of atorvastatin but not pravastatin.
Stephen Donahue MD, Leonard Lachman MD, Jean Norton MS, John Franc BS and Laishun Chen PhD
Clin Pharmacol Ther 65: 179; doi:10.1016/S0009-9236(99)80248-3
Pharmacodynamic-pharmacokinetic interrelations of the GPIIb/IIIa-antagonist YM337.
S. Harder MD, U. Klinkhardt MD and H.K. Breddin MD
Clin Pharmacol Ther 65: 179; doi:10.1016/S0009-9236(99)80249-5
Grapefruit juice increases serum simvastatin and atorvastatin but not pravastatin.
P.J. Neuvonen MD, J. Lilja MD and K.T. Kivistö MD
Clin Pharmacol Ther 65: 180; doi:10.1016/S0009-9236(99)80250-1
Rifampin impairs steady-state bioavailability of talinolol: Potential role of P-gp.
W. Siegmund MD, K. Westphal, A. Weinbrenner, M. Zschiesche PhD, G. Franke PhD, M. Knoke MD, P. Fritz MD, T. Hachenberg MD, B. Terhaag MD and H.K. Kroemer PhD
Clin Pharmacol Ther 65: 180; doi:10.1016/S0009-9236(99)80251-3
Pharmacokinetics (PK) and pharmacodynamics (PD) of lanoteplase in healthy subjects.
N. Vachharajani PhD, W. Shyu PhD, B. Stouffer BS, R. Raymond MS, W. Liao MD, PhD and L. Tay PhD
Clin Pharmacol Ther 65: 180; doi:10.1016/S0009-9236(99)80252-5
Modeling the anomalous pharmacokinetics of amiodarone.
M. Weiss PhD
Clin Pharmacol Ther 65: 180; doi:10.1016/S0009-9236(99)80253-7
Pharmacokinetics and safety of single IV doses of AMP 579 (RPR 100579) in patients with renal insufficiency.
P.N. Zannikos PhD, B.K. Jensen PhD, R. Baybutt PhD, B. Boutouyrie MD, M. Varma MD, E.P. Dorval RN, T. McGowan MD, S.A. Waldman MD, PhD and H.E. Greenberg MD
Clin Pharmacol Ther 65: 181; doi:10.1016/S0009-9236(99)80254-9
Effect of obesity on the pharmacokinetics of an adenosine receptor agonist, AMP 579.
P.N. Zannikos PhD, R.I. Baybutt PhD, L. Tripp, B.X. Boutouyrie MD, P.T. Leese MD and B.K. Jensen PhD
Clin Pharmacol Ther 65: 181; doi:10.1016/S0009-9236(99)80255-0
Prediction of the effect of systemic acidosis (SA) on lidocaine (L) disposition kinetics in pigs using a physiologically based pharmacokinetic (PBPK) model.
H. Zhao PhD, H. Sun PhD and M.S.S. Chow PharmD
Clin Pharmacol Ther 65: 181; doi:10.1016/S0009-9236(99)80256-2
Applying modeling and simulation to improve the design of a clinical efficacy trial.
M.R. Gastonguay PhD, H.S. Pentikis PhD, M.T. Alexander MS and L. Lee
Clin Pharmacol Ther 65: 181; doi:10.1016/S0009-9236(99)80257-4
Modeling uncertainty in clinical trial simulations: A bayesian approach.
W.R. Gillespie PhD, M. Sale MD and M.R. Gastonguay PhD
Clin Pharmacol Ther 65: 182; doi:10.1016/S0009-9236(99)80258-6
Design of a phase II efficacy trial for a GPIIb/IIIa antagonist using computer simulation.
D.R. Wada PhD, K. Engleman MS, S. Ellis PhD, M. Warwick PhD, P. Marshall PhD, M. Scott PhD, A. Raza MD and B. Bryzinski MD
Clin Pharmacol Ther 65: 182; doi:10.1016/S0009-9236(99)80259-8
Calibration of a fallible instrument for measuring patient compliance.
L.A. Kenna BS and L.B. Sheiner MD
Clin Pharmacol Ther 65: 182; doi:10.1016/S0009-9236(99)80260-4
Cost-effectiveness of routine screening for statin-induced hepatitis.
D.F. Lehmann MD, PharmD, R. Connell, J. Medicis PharmD, N. Newman MS and P. Shanahan MD
Clin Pharmacol Ther 65: 182; doi:10.1016/S0009-9236(99)80261-6
The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting.
M.U. Shad MD, C.A. Carmichael, S.H. Preskorn MD and W.D. Horst PhD
Clin Pharmacol Ther 65: 183; doi:10.1016/S0009-9236(99)80262-8
Acetaminophen (APAP) ingestions in children: A 10 year review.
S. Alander, M.D. Dowd, S. Bratton and G.L. Kearns
Clin Pharmacol Ther 65: 183; doi:10.1016/S0009-9236(99)80263-X
Power calculations for pharmacogenomic association studies.
D.A. Katz PhD and N.J. Schork PhD
Clin Pharmacol Ther 65: 183; doi:10.1016/S0009-9236(99)80264-1
Correlation between phenotypes of FMO obtained by ranitidine N-oxidation and genotypes of FMO3 in a Korean population.
Y.N. Cha PhD, K.H. Lee MD, W.G. Chung PhD, C.S. Park PhD, J.H. Kang MD, H.M. Baek MD, J.S. Kang MD and H.K. Roh MD
Clin Pharmacol Ther 65: 183; doi:10.1016/S0009-9236(99)80265-3
Ethnic differences of FMO3 gene mutant alleles.
J.H. Kang MD, C.S. Park PhD, K.H. Lee MD, W.G. Chung PhD, H.M. Baek MD, H.K. Roh MD, Y.N. Cha PhD, D.G. McCarver, J.R. Whestine BS and R.N. Hines PhD
Clin Pharmacol Ther 65: 184; doi:10.1016/S0009-9236(99)80266-5
Absence of dose-dependency for CYP2D6 phenotyping (PT) with dextromethorphan (DM).
D.S. Streetman PharmD, R.E. Ellis MD, J.S. Leeder PharmD, PhD, A. Gaedigk PhD, R. Gotschall BS, G.L. Kearns PharmD and J.S. Bertino Jr PharmD
Clin Pharmacol Ther 65: 184; doi:10.1016/S0009-9236(99)80267-7
The Genetic Analysis of CYP2C9 Polymorphism in A Korean Population
Y.R. Yoon MD, PhD, J.H. Shon MD, H.R. Lee MS, I.J. Cha MD, PhD and J.G. Shin MD, PhD
Clin Pharmacol Ther 65: 184; doi:10.1016/S0009-9236(99)80268-9
MPA protein Binding in Uremic Plasma: Prediction of Free Fraction
H.U. Meier Kriesche MD, B. Kaplan MD, M. Korecka PhD, S. Mulgaonkar MD, G. Friedman MD, K. Brayman MD, PhD and L.M. Shaw MD
Clin Pharmacol Ther 65: 184; doi:10.1016/S0009-9236(99)80269-0
Optimal Plasma Sampling to Predict AUC of The CYP3A Probe Midazolam (MID)
J.S. Kim PharmD, A.D.M. Kashuba PharmD, A.N. Nafziger MD, M.L. Rocci Jr PhD, R.W. Kulawy BS, D.J. Beck BS and J.S. Bertino Jr PharmD
Clin Pharmacol Ther 65: 185; doi:10.1016/S0009-9236(99)80270-7
Estimation of Patient Compliance Using A Bayesian Approach FREE
S. Mu MS and T.M. Ludden PhD
Clin Pharmacol Ther 65: 185; doi:10.1016/S0009-9236(99)80271-9
A method to Assess Congruence of A Clinical Trial Simulation (CTS) and A Phase II Clinical Study
P.N. Mudd Jr. PharmD, M. Hale PhD, Y. Shen PhD, R.L. O'Connor-Semmes PhD and M. Sale MD
Clin Pharmacol Ther 65: 185; doi:10.1016/S0009-9236(99)80272-0
Effect of Renal Impairment on The Pharmacokinetics of Rosiglitazone (RSG)
M.C. Chapelsky PharmD, K. Thompson PhD, A. Miller PhD, M. Sack MD, R. Blum PharmD, D. Jorkasky MD, M.I. Freed MD and SmithKline Beecham
Clin Pharmacol Ther 65: 185; doi:10.1016/S0009-9236(99)80273-2
Effect of Hepatic Impairment on The Pharmacokinetics (PK) of Rosiglitazone (RSG)
A.K. Miller PhD, A.L. Inglis PhD, K. Thompson PhD, C.C. Davie BSc, S. Schenker MD, R. Blum PharmD, D. Jorkasky MD, M.I. Freed MD and SmithKline Beecham
Clin Pharmacol Ther 65: 186; doi:10.1016/S0009-9236(99)80274-4
Pharmacokinetics of Rosiglitazone are Unaltered in Hemodialysis Patients
K. Thompson PhD, B. Zussman BSc, A. Miller PhD, D. Jorkasky MD, M. Freed MD and SmithKline Beecham
Clin Pharmacol Ther 65: 186; doi:10.1016/S0009-9236(99)80275-6
Effect of Troglitazone on PK and PD of Atorvastatin
C.M. Loi PharmD, R. Stern MD, PhD, R. Abel PhD, J.R. Koup PharmD, A.B. Vassos MD and A.J. Sedman MD, PhD
Clin Pharmacol Ther 65: 186; doi:10.1016/S0009-9236(99)80276-8
Effect of Troglitazone on Fexofenadine Pharmacokinetics
C.M. Loi PharmD, J.R. Koup PharmD, A.B. Vassos MD and A.J. Sedman MD, PhD
Clin Pharmacol Ther 65: 186; doi:10.1016/S0009-9236(99)80277-X
Lack of Effect of Orlistat on The Pharmacokinetics and Pharmacodynamics of Pravastatin
C. Oo PharmD, PhD, B. Akbari PharmD, S. Lee PhD, G. Nichols MD and C. Hellmann BS
Clin Pharmacol Ther 65: 187; doi:10.1016/S0009-9236(99)80278-1
The Pharmacokinetic Profile of Theophylline is Not Significantly Altered by Repaglinide Co-Administration
M.S. Thomsen PhD, V. Hatorp MSc and M. Seiberling MD, PhD
Clin Pharmacol Ther 65: 187; doi:10.1016/S0009-9236(99)80279-3
Disposition of One Dose of 14C-Repaglinide During Non-Labeled Repaglinide Multiple Dosing
V. Hatorp MSc, P.N.M. Van Heiningen PhD, RPh, J.J. Van Lier MD, N.C. Van de Merbel PhD, K.K. Nielsen PhD, K.T. Hansen PhD and J.H.G. Jonkman PhD, FCP, RPh
Clin Pharmacol Ther 65: 187; doi:10.1016/S0009-9236(99)80280-X
Repaglinide Pharmacokinetics in Healthy & Chronic Liver Disease Subjects
V. Hatorp MSc and G. Haug-Pihale MD, PhD
Clin Pharmacol Ther 65: 187; doi:10.1016/S0009-9236(99)80281-1
Influence of Menstrual Cycle on Cytochrome (CYP) P450 Enzyme Activity: Results of A Pilot Trial
J. McCune PharmD, A. Kashuba PharmD, J. Decker PharmD, A. Meadowcroft PharmD, K. Williamson PharmD, J. Pieper PharmD and C. Lindley PharmD
Clin Pharmacol Ther 65: 188; doi:10.1016/S0009-9236(99)80282-3
PPAR-Dependent Induction of Renal CYP4A Expression by Fasting
D.L. Kroetz PhD, D.S. Waddell BS, A. Schweizer MS, P. Bianchi BS, N. Ladouce BS and T. Pineau PhD
Clin Pharmacol Ther 65: 188; doi:10.1016/S0009-9236(99)80283-5
Rapid Aldosterone Effects in Healthy Male Volunteers Detected by Impedance Cardiography
B.M.W. Schmidt MD, A. Montealegre MD, C.P. Janson PhD, A. Scherhag MD, M. Christ MD, M. Feuring MD and M. Wehling MD
Clin Pharmacol Ther 65: 188; doi:10.1016/S0009-9236(99)80284-7
Hypoxia-Induced Attenuation of Rapid Aldosterone Effects on Skeletal Muscle Metabolism
M. Christ MD, J. Zange PhD, C. Janson PhD, K. Müller MD, B.M.W. Schmidt MD, R. Gerzer MD and M. Wehling MD
Clin Pharmacol Ther 65: 188; doi:10.1016/S0009-9236(99)80285-9
Pharmacokinetics and Pharmacodynamics of A Novel Vasopressin Receptor Antagonist, VPA-985, in Healthy Subjects
G. Muralidharan PhD, X. Meng PhD, S.A. DeCleene RN, W.H. Cevallos PhD, R. Fruncillo MD, PhD, D. Hicks PhD and G.P. Orczyk MD, PhD
Clin Pharmacol Ther 65: 189; doi:10.1016/S0009-9236(99)80286-0
Pharmacokinetics and Safety of Multiple Oral Doses of LY333531, A PKC Inhibitor, in Healthy Subjects
D. Demolle PhD, J.-M. De Suray MS and C. Onkelinx MD
Clin Pharmacol Ther 65: 189; doi:10.1016/S0009-9236(99)80287-2
Risedronate Pharmacokinetics Upon Multiple Dose Oral Administration to Postmenopausal Women for Six Months
D.Y. Mitchell PhD, G.A. Thompson PhD, R.A. Eusebio MS, K.A. Pallone PharmD, M.E. Clay BA, D.A. Russell BS, J.D. Nesbitt BS and J.H. Powell MD
Clin Pharmacol Ther 65: 189; doi:10.1016/S0009-9236(99)80288-4
Single (SD) and Multiple Dose (MD) Pharmacokinetics (PK) of Estradiol (E2) and Estrone (E1) in Postmenopausal Women (PMW) FREE
J. Shi MD, A. Melikian PharmD, PhD and P. Hinderling MD, PhD
Clin Pharmacol Ther 65: 189; doi:10.1016/S0009-9236(99)80289-6
Population Pharmacokinetic (PK) Modeling of Microencapsulated Octreotide Acetate (MOA) in Healthy Subjects
H. Zhou PhD, T.-L Chen MD, T. Miller PhD, M. Marino MD, H. Lau PhD and J. McLeod MD
Clin Pharmacol Ther 65: 190; doi:10.1016/S0009-9236(99)80290-2
A pharmacokinetic Model Discriminates Exogenous and Endogenous Growth Hormone Input
J.J. Lima PharmD and G.M. Bright MD
Clin Pharmacol Ther 65: 190; doi:10.1016/S0009-9236(99)80291-4
Assessment of Medications in Elderly, Ambulatory Veterans at Risk for Falls
G.T. Jamison PharmD, M. Burlingame PharmD, D.T. Lowenthal MD, PhD, A. Herrera MD, V. Bhatnagar MD, B. Chong PharmD, S. Lees PharmD, S. Machuca PharmD and J. Maruenda MD
Clin Pharmacol Ther 65: 190; doi:10.1016/S0009-9236(99)80292-6
Gender Variations in Effect of Sertraline on Behavioral Disorders (BD) in Alzheimer's Disease (AD)
K.L. Lanctôt PhD, N. Herrmann MD, G. Eryavec MD, R. van Reekum MD and C.A. Naranjo MD
Clin Pharmacol Ther 65: 190; doi:10.1016/S0009-9236(99)80293-8
Reducing Medication-Related Fall Risk in The Elderly
P.W. Slattum PharmD, PhD and P.W. Maynard PhD
Clin Pharmacol Ther 65: 191; doi:10.1016/S0009-9236(99)80294-X
Central (CE) Vs. Peripheral (PE) Effects of I.V. Bolus Scopolamine (SCP) in Healthy Young and Elderly Females
J.D. Hong BS, P.W. Slattum PharmD, PhD, S.M. Learned-Coughlin PharmD, PhD, K. Wesnes PhD and J. Venitz MD, PhD
Clin Pharmacol Ther 65: 191; doi:10.1016/S0009-9236(99)80295-1
Drug Supplies and Costs for Older Adults
M. Marray PharmD, K. Stroupe PhD, T. Stump MAS and C. Callahan MD
Clin Pharmacol Ther 65: 191; doi:10.1016/S0009-9236(99)80296-3
Comparison of Clearance of Three CYP 3A4/5 Substrates in Patients
C. Barnas MS, M.E. Krecic-Shepard PhD, J. Slimko RN and J.B. Schwartz MD
Clin Pharmacol Ther 65: 191; doi:10.1016/S0009-9236(99)80297-5
The Effect of Estrogen Replacement Therapy on CYP3A Activity
B.D. Haehner-Daniels MD, J.C. Gorski PhD, R. Carven RN, S.A. Wrighton PhD, J.A. Clements BS, M.A. Bruce MD and S.D. Hall PhD
Clin Pharmacol Ther 65: 192; doi:10.1016/S0009-9236(99)80298-7
Grapefuit Juice-Felodipine Interaction in Healthy Seniors
G.K. Dresser MD, D.G. Bailey PhD and S.G. Carruthers MD
Clin Pharmacol Ther 65: 192; doi:10.1016/S0009-9236(99)80299-9
Levormeloxifene: Safety & Pharmacokinetics in Young Versus Elderly Postmenopausal Women
B.K. Skrumsager MSc, M. Müller MD and B. Kiehr DVM
Clin Pharmacol Ther 65: 192; doi:10.1016/S0009-9236(99)80300-2
Effect of Oral Contraceptives and Hormone Replacement Therapy on The Clearance of Cytochrome P450 3A4/5 Substrates
M.E. Krecic-Shepard PhD, C. Barnas MS, J. Slimko RN, C. Gorski PhD, I. Wainer PhD and J.B. Schwartz MD
Clin Pharmacol Ther 65: 193; doi:10.1016/S0009-9236(99)80301-4
Grapefruit Juice-Warfarin Interaction in Anticoagulated Patients
G.K. Dresser MD, C. Munoz MD, M. Cruikshank MD, M. Kovacs MD and J.D. Spence MD
Clin Pharmacol Ther 65: 193; doi:10.1016/S0009-9236(99)80302-6
Studies of FLT3 Ligand Alone and in Combination With GM-CSF or G-CSF in Healthy Volunteers
M.E. Lebsack, J. Hoek, A. Feng and D. Caron
Clin Pharmacol Ther 65: 193; doi:10.1016/S0009-9236(99)80303-8
Sickle Cell Disease and Aspartame
C.V. Manion MD, B. Ogle, J. Parkhurst MD and A.B. Edmundson PhD
Clin Pharmacol Ther 65: 194; doi:10.1016/S0009-9236(99)80304-X
Ecarin Time Superior to Aptt in Monitoring Peghirudin Effects
R. Velagapudi PhD, J.J. Badimon PhD, P. Kyrle MD, M. Sujatta MD, J. Bodnar, R. Faulkner PhD, S. Fettner, W. Hull and J. Cheesbro MD
Clin Pharmacol Ther 65: 194; doi:10.1016/S0009-9236(99)80305-1
Determinants of Warfarin S:R Ratio in Orthopedic Surgery (OS) Patients
J.S. Leeder, A. Gaedigk, G. Gupta, S. Simon, K. Henne, K. Allen and A. Rettie
Clin Pharmacol Ther 65: 194; doi:10.1016/S0009-9236(99)80306-3
Sensitivity to Initial Conditions as A Source of PK Variability
M. Wachsman MD, PhD, C.H. Mielke MD and J.A. Hayes PhD
Clin Pharmacol Ther 65: 194; doi:10.1016/S0009-9236(99)80307-5
Preliminary Pharmacokinetics (PK) of COL-3, A Matrix Metalloproteinase (MMP) Inhibitor
Michelle A. Rudek BS, Valerie Dyer RN, J. Michael Hamilton MD, James M. Pluda MD, Eddie Reed MD and William D. Figg PharmD
Clin Pharmacol Ther 65: 195; doi:10.1016/S0009-9236(99)80308-7
Bias Control in Open Label Comparative Oncology Trials: Role of an Independent Tumor Response Evaluation Committee (TREC)
Mark W. Russo MD, PhD, Patricia Devitt PharmD, Robert Ott, Mary Anne Janzcak and Robert T. Heelan MD
Clin Pharmacol Ther 65: 195; doi:10.1016/S0009-9236(99)80309-9
The Effect of Rifampin on The Pharmacokinetics of Oral and Intravenous Ondansetron
K. Villikka MD, K.T. Kivistö MD and P.J. Neuvonen MD
Clin Pharmacol Ther 65: 195; doi:10.1016/S0009-9236(99)80310-5
Dexamethasone Induction of Cytochrome P450 3A4 Activity in Human Hepatocytes and Healthy Volunteers
J. McCune PharmD, R. Hawke PhD, E. LeCluyse PhD, H. Gillenwater MD, J. Ritchie PhD and C. Lindley PharmD
Clin Pharmacol Ther 65: 195; doi:10.1016/S0009-9236(99)80311-7
Reduced CYP2C19 Activity in Cancer Patients
M.L. Williams PhD, P. Bhargava MD, J.L. Marshall MD, D.A. Flockhart MD and I.W. Wainer PhD
Clin Pharmacol Ther 65: 196; doi:10.1016/S0009-9236(99)80312-9
Cisplatin-Induced Apoptosis in Melanoma Cells
A. Lau PharmD, C.J. Li MS, A. Santos MS, M. Warso MD, T. Das Gupta MD, R. Yu PhD and T. Kong PhD
Clin Pharmacol Ther 65: 196; doi:10.1016/S0009-9236(99)80313-0
Population Pharmacodynamics of LY231514 in Patients With Cancer
A.P. Periclou PhD, D. Ouellet PhD, R.D. Johnson PhD, J.M. Woodworth PhD and R.L. Lalonde PharmD
Clin Pharmacol Ther 65: 196; doi:10.1016/S0009-9236(99)80314-2
A cytokinetic Model Describes The Granulopoietic Effects of r-metHuG-CSF-SD/01 (SD/01) and The Homeostatic Regulation of SD/01 Clearance in Normal Volunteers
L.K. Roskos PhD, B. Yang PhD, G. Schwab MD, P. Lockbaum, G. Molineux PhD, K. Khoo MS, T. Hunt MD and E.N. Cheung PhD
Clin Pharmacol Ther 65: 196; doi:10.1016/S0009-9236(99)80315-4
High Variability in SN-38 Glucuronidation in Liver Samples from African Population as Predicted by UGT1A1 Genotypes
L. Iyer PhD, A.C. Bergseth BS, G. Ybazeta BS, M.V. Relling PharmD, M.J. Ratain MD and A. DiRienzo PhD
Clin Pharmacol Ther 65: 197; doi:10.1016/S0009-9236(99)80316-6
Limited Sampling Models for Irinotecan Pharmacokinetics
J.A. Sloan, P. Atherton Skaff, J. Reid, H. Pitot, C. Erlichman and L. Schaaf
Clin Pharmacol Ther 65: 197; doi:10.1016/S0009-9236(99)80317-8
Bioavailability of Oral O 6-Benzylguanine in Rats
R.B. Ewesuedo MD and M.E. Dolan PhD
Clin Pharmacol Ther 65: 197; doi:10.1016/S0009-9236(99)80318-X
A Pharmacokinetic (PK) Model for Irinotecan and Its Metabolites in Cancer Patients
C. Klein BA, H. Kastrissios PhD, E. Gupta PhD and M. Ratain MD
Clin Pharmacol Ther 65: 197; doi:10.1016/S0009-9236(99)80319-1
Bovine Serum Albumin Enhances Vinblastine Efflux in Caco-2 Cells
J.D. Huang PhD, C.Y. Hsu MS and Y.L. Lo PhD
Clin Pharmacol Ther 65: 198; doi:10.1016/S0009-9236(99)80320-8
PD Modeling of Three Chemotherapeutic Agents and Human Lung Tumor Cells
Judith M. Hyatt, Sherry Mangione and Jerome J. Schentag
Clin Pharmacol Ther 65: 198; doi:10.1016/S0009-9236(99)80321-X
Application of Clinical Trial Simulation in Exploring The Safety Profile of Docetaxel (D) in Cancer Patients
C. Veyrat-Follet, R. Bruno, G. Montay and G.R. Rhodes
Clin Pharmacol Ther 65: 198; doi:10.1016/S0009-9236(99)80322-1
Mitomycin C (MMC) combined with paclitaxel (PCTX)-a clinical and pharmacokinetic study.
L.D. Lewis MD, P.A. Kaufman, S. Anthony, A. Nervi, B. Beaulieu, K. MacKay, R. Barth, M.S. Ernstoff, D.W. Nierenberg and J.W. Hamilton
Clin Pharmacol Ther 65: 198; doi:10.1016/S0009-9236(99)80323-3
Influence of antipsychotic, antiemetic, and antifungal drugs of the function of P-glycoprotein in Caco-2 cells.
S. Ibrahim PhD, A. Knapton BS, T. Licht PhD and A. Aszalos PhD, FDA
Clin Pharmacol Ther 65: 199; doi:10.1016/S0009-9236(99)80324-5
A population pharmacokinetic metabolism model for individualizing ciprofloxacin therapy in ophthalmology.
M. Pasternyk (DiMarco) MSc, J. Chen MD, I.W. Wainer PhD and M.P. Ducharme PharmD
Clin Pharmacol Ther 65: 199; doi:10.1016/S0009-9236(99)80325-7
Randomized trial of varicella zoster immune globulin (VZIG) to prevent or modify the course of varicella zoster virus (VZV) infection in pregnant women.
G. Inocencion BSc, R. Loebstein MD, A. Lalkin MD, R. Geist MD, D. D'Alimonte BSc, M. Petric PhD, B. Woloski PhD and G. Koren MD
Clin Pharmacol Ther 65: 199; doi:10.1016/S0009-9236(99)80326-9
Pharmacologic and non-pharmacologic management of nausea and vomiting of pregnancy; A systematic critical review of the safety and effectiveness of treatment.
P. Mazzotta MSc and L.A. Magee MD FRCP(C), MSc
Clin Pharmacol Ther 65: 199; doi:10.1016/S0009-9236(99)80327-0
The perception of teratogenic risk by women with nausea and vomiting of pregnancy.
P. Mazzotta MSc, L.A. Magee MD, FRCPC, MSc and G. Koren MD, ABMT, FRCPC
Clin Pharmacol Ther 65: 200; doi:10.1016/S0009-9236(99)80328-2
Dose-finding study of IV nitroglycerin for the treatment of preterm labor using a continual reassessment method.
J.M. Treluyer MD, PhD, M. De Spirlet MD, S. Chevret MD, PhD, E. Rey PharmD, M. Tournaire MD, PhD, D. Cabrol MD, PhD and G. Pons MD, PhD
Clin Pharmacol Ther 65: 200; doi:10.1016/S0009-9236(99)80329-4
Accelerated N-glucuronidation of nicotine and cotinine during pregnancy.
D.A. Dempsey MD, P. Jacob III PhD and N.L. Benowitz MD
Clin Pharmacol Ther 65: 200; doi:10.1016/S0009-9236(99)80330-0
Choice of breastfeeding and physicians' advice: A cohort study of women receiving propylthiouracil.
A. Lee BSc, M.E. Moretti BSc, A. Collantes, D. Chong, P. Mazzotta MSc, G. Koren MD, S.S. Merchant and S. Ito MD
Clin Pharmacol Ther 65: 200; doi:10.1016/S0009-9236(99)80331-2
Assessment of maternal and fetal concentrations of piperacillin by a population approach.
G. Paintaud MD, PhD, F. Odoul PharmD, C. Le Guellec PharmD, PhD, P. Roth MD, P.R. Bechtel MD, PhD and E. Autret-Leca MD, PhD
Clin Pharmacol Ther 65: 201; doi:10.1016/S0009-9236(99)80332-4
Clinical pharmacology studies in patients with renal impairment (RI): Past experience and regulatory perspectives.
S. Ibrahim PhD, S. Huang PhD, W. Gillespie PhD, P. Honig PhD, H. Malinowski PhD, R. Williams PhD and L. Lesko PhD, FDA
Clin Pharmacol Ther 65: 201; doi:10.1016/S0009-9236(99)80333-6
Pharmacokinetic (PK) and pharmacodynamic (PD) interaction between OPC-41061 (OPC), furosemide (F) and hydrochlorothiazide (H).
B. Tammara PhD, P. Bricmont PhD and S. Bramer PhD
Clin Pharmacol Ther 65: 201; doi:10.1016/S0009-9236(99)80334-8
Effect of sulfisoxazole on the pharmaco-dynamics of furosemide in patients with nephrotic syndrome.
J. Gorski PhD, Y. Liu MD, K. Sundblad RN, D.C. Brater MD and R. Agarwal MD
Clin Pharmacol Ther 65: 201; doi:10.1016/S0009-9236(99)80335-X
Dose-response modeling of recombinant human erythropoietin (rhEPO) in chronic renal failure (CRF) patients.
K.S. Bae MD, K.S. Yu MD, I.J. Jang MD, S.G. Shin MD, C.S. Lim MD, J.S. Park MD, H.Y. Oh MD and C. Ahn MD
Clin Pharmacol Ther 65: 202; doi:10.1016/S0009-9236(99)80336-1
Safety and pharmacokinetics of alfuzosin 10 mg once daily formulation comparatively to standard formulation (2.5 mg tid) in elderly subjects.
J.L. Pinquier MD, H. Fuder MD, J. Amersdorffer MD, N. Lilienthal PharmD, C. Rauch-Dessanti PhD, A. Delfolie MSc and P. Rosenzweig MD
Clin Pharmacol Ther 65: 202; doi:10.1016/S0009-9236(99)80337-3
Pharmacodynamics(PD) and kinetics (PK) of bivalirudin (BIV) in renal failure (RF) and hemodialysis (HD).
W. Irvin, D. Sica MD, T. Gehr MD, A. McAllister MSC, M. Rogge PhD, S. Charenkavanich PhD and B. Adelman MD
Clin Pharmacol Ther 65: 202; doi:10.1016/S0009-9236(99)80338-5
Pharmacokinetics (PK) of warfarin in hemodialysis (HD) patients.
L. Lambrecht PharmD, S. Swan MD and R. Berkseth MD
Clin Pharmacol Ther 65: 202; doi:10.1016/S0009-9236(99)80339-7
Orbofiban single dose pharmacokinetics (PK) and pharmacodynamics (PD) in renal failure (RF) and hemodialysis (HD).
D. Sica MD, T. Gehr MD, A. Ogunremi MD, I. Fakhry BS, J. Ruddley BS, A. Karim PhD and R. Anders PharmD
Clin Pharmacol Ther 65: 203; doi:10.1016/S0009-9236(99)80340-3
Dialysis clearance of gadoversetamide (G).
S. Swan MD, S. Andersen RPh, L. Lambrecht PharmD, J. Baker PhD and J. Pierro MD
Clin Pharmacol Ther 65: 203; doi:10.1016/S0009-9236(99)80341-5
Pharmacokinetics (PK) of SDZ HTF 919 (HTF) not altered in subjects with severe renal insufficiency requiring hemodialysis.
H. Zhou PhD, J. McLeod MD, L. Alladina PharmD, M. Guerret PhD, S. Osborne MS, H. Lau PhD, L. Lambrecht PharmD and S.K. Swan MD
Clin Pharmacol Ther 65: 203; doi:10.1016/S0009-9236(99)80342-7
Clinical trial simulation: Retrospective analysis of dose ranging trials in detrusor instability with tolterodine.
M.B. Schoenhoff PhD and J.W. Mandema PhD
Clin Pharmacol Ther 65: 203; doi:10.1016/S0009-9236(99)80343-9
Transgenic mice with cardiomyopathy — An attractive model for drug development?
B.C. Knollmann MD, K.K. Trivedi MD, N.J. Weissman MD and M. Morad PhD
Clin Pharmacol Ther 65: 204; doi:10.1016/S0009-9236(99)80344-0
An inverse association between -tocopherol and soluble P-selectin levels in patients with coronary artery disease.
C. Parker III MD and J.E. Freedman MD
Clin Pharmacol Ther 65: 204; doi:10.1016/S0009-9236(99)80345-2
Differences in the frequency of Arg492
Cys polymorphism of the human 1A-adrenergic receptor (1A-AR) in African-Americans (AA) and Caucasians (CA).
R.B. Kim MD, H.G. Xie MD, PhD, C.M. Stein MD, J.V. Gainer MD, N.J. Brown MD and A.J.J. Wood MD
Clin Pharmacol Ther 65: 204; doi:10.1016/S0009-9236(99)80346-4
A kinetic-dynamic model for perindoprilat effects in healthy volunteers and in congestive heart failure patients.
E. Bellissant MD, PhD and J.F. Giudicelli MD, PhD
Clin Pharmacol Ther 65: 204; doi:10.1016/S0009-9236(99)80347-6
The expression of the human organic cation transporter hOCT1 in mammary gland.
U. Dhillon BSc, J. Shenton, V. Cook MSc, P. Harper PhD, J. Watson-Macdonell RN, MSc and S. Ito MD
Clin Pharmacol Ther 65: 205; doi:10.1016/S0009-9236(99)80348-8
OATP and P-glycoprotein mediate the uptake and excretion of fexofenadine.
R.B. Kim MD, M. Cvetkovic MD, M.F. Fromm MD, B. Leake BSc and G.R. Wilkinson PhD
Clin Pharmacol Ther 65: 205; doi:10.1016/S0009-9236(99)80349-X
Loperamide causes respiratory depression when P-gp is inhibited.
A.J.M. Sadeque PhD, C. Wandel MD, S. Shah and A.J.J. Wood MD
Clin Pharmacol Ther 65: 205; doi:10.1016/S0009-9236(99)80350-6
Grapefruit juice exerts stimulatory effects on P-glycoprotein.
A. Soldner PhD, U. Christians MD, PhD, M. Susanto BSc, V.J. Wacher PhD, J.A. Silverman PhD and L.Z. Benet PhD
Clin Pharmacol Ther 65: 205; doi:10.1016/S0009-9236(99)80351-8
Notes of the American Society for Clinical Pharmacology and Therapeutics
"A bill abrams legacy: Education in clinical drug evaluation for the new millenium"
Clin Pharmacol Ther 65: 206; doi:10.1016/S0009-9236(99)80352-X
